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ABSTRACT OF THE DISSERTATION 
THE DEGRADATION OF PHARMACEUTICAL POLLUTANTS IN 
WASTEWATER CATALYZED BY CHLOROPEROXIDASE AND THE 
CONSTRUCTION OF CHLOROPEROXIDASE H105R MUTANT 
by 
Qinghao He 
Florida International University, 2016 
Miami, Florida 
Professor Xiaotang Wang, Major Professor 
Trace amounts of pharmaceuticals have been detected in water, from 
nanograms per liter to micrograms per liter, and have a negatively effect in the 
aquatic environment and an increased potential risk of drug poisoning for human 
and animals. In order to address the problem, drug degradation catalyzed by 
chloroperoxidase (CPO) has been investigated. CPO is a heme-containing 
glycoprotein secreted by the fungus, Caldariomyces fumago, it catalyzes two 
major types of oxidations, two one-electron oxidations as catalyzed by most 
peroxidases and two-electron oxidations which are rare for conventional 
peroxidases.  
Five common drugs from a variety of classes (acetaminophen, 
carbamazepine, sulfamethazine, diclofenac and naproxen) which were persistent 
in the environment have been studied. The metabolites of each drug were 
identified and the pathways of degradation were proposed. All of them were 
found to be 100% degradation efficiency in the CPO-H2O2-Cl
-  system which the 
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catalyzation only required low concentration of CPO (normally nanomolar level) 
as well as relatively low concentration of H2O2 as cofactor. This degradation 
method is economic and highly efficient, the results of my experiment extensively 
support the hypothesis that CPO has a great potential in the environmental 
application. 
A new mutant of CPO has been constructed to investigate the role of 
histidine 105 in the active site of distal pocket. Histidine 105 was suggested to 
play an essential role in modulating the chlorination activity by forming hydrogen 
bond with glutamic acid 183, histidine has been replaced by arginine to generate 
CPO H105R mutant. The construction and transformation were a success but the 
protein was expressed as apoenzyme, suggesting the mutagenesis to a larger 
arginine residue at position105 disturbed the heme incorporation. 
 
 
 
 
 
 
 
 
 
 
 
ix 
 
TABLE OF CONTENTS 
CHAPTER                                                                                                      PAGE 
I. INTRODUCTION........................................................................................................... 1 
1.1 The occurrence of pharmaceutical pollutants in water ................................... 1 
1.2 The treatment for removal of pharmaceuticals in water ................................. 3 
1.3 The structure of CPO ........................................................................................... 6 
1.4 The mechanism of CPO catalyzed reactions ................................................. 10 
1.5 CPO catalyzed reactions ................................................................................... 11 
    1.5.1 One-electron oxidations ............................................................................. 11 
    1.5.2 Two-electron oxidations ............................................................................. 14 
 
II. CPO-CATALYZED CHLORINATION AND POLYMERIZATION OF 
ACETAMINOPHEN................................................................................................ 18 
2.1. Background......................................................................................................... 18 
2.2 Experimental Procedure .................................................................................... 18 
2.2.1 Material ......................................................................................................... 18 
2.2.2 UV-Visible spectrophotometry .................................................................. 19 
2.2.3 Liquid chromatography and mass spectrometry.................................... 19 
2.3 Result and discussion ........................................................................................ 22 
    2.3.1 UV-Vis study of CPO-catalyzed degradation of APAP ......................... 22 
    2.3.2 LC-Q-TOF- MS ............................................................................................ 23 
    2.3.3 Triple-quadruple LC/MS/MS ...................................................................... 25 
2.4 Discussion ............................................................................................................ 33 
 
III. CPO-CATALYZED DEGRADATION OF CARBAMAZEPINE ........................... 35 
3.1 Background .......................................................................................................... 35 
3.2 Experimental Procedure .................................................................................... 36 
3.2.1 Material ......................................................................................................... 36 
3.2.2 UV-Visible spectrophotometry .................................................................. 36 
3.2.3 Liquid chromatography and mass spectroscopy ................................... 38 
3.3 Result and discussion ........................................................................................ 40 
3.3.1 UV-Vis study of CP O-catalyzed degradation of carbamazepine ....... 40 
3.3.2 The effect of chloride on the degradation of CBZ.................................. 41 
3.3.3 The effect of pH on the degradation of CBZ........................................... 43 
3.3.4 The effect of H2O2 concentration ............................................................ 43 
3.3.5 The kinetic parameters of CBZ degradation catalyzed by CPO ......... 44 
3.3.6 LC-Q-TOF- MS ............................................................................................ 45 
3.3.7 Triple-Quadruple LC/MS/MS..................................................................... 52 
3.4 Discussion ............................................................................................................ 58 
 
IV. CPO-CATALYZED DEGRADTION OF SULFAMETHAZINE ........................... 61 
4.1 Background .......................................................................................................... 61 
4.2 Experimental Procedure .................................................................................... 61 
x 
 
4.2.1 Material ......................................................................................................... 61 
4.2.2 UV-Visible spectrophotometry .................................................................. 61 
4.2.3 Liquid chromatography and mass spectrometry.................................... 62 
4.3 Result and discussion ........................................................................................ 64 
4.3.1 UV-Vis study of CPO-catalyzed degradation of carbamazepine ........ 64 
4.3.2 LC-Q-TOF- MS ............................................................................................ 65 
4.4 Discussion ............................................................................................................ 78 
 
V. ENGINEERING THE HYDROGEN BOND OF CPO BY MUTANT H105R ..... 81 
5.1 Introduction .......................................................................................................... 81 
5.2 Experimental Procedure .................................................................................... 82 
5.2.1 Materials ....................................................................................................... 82 
5.2.2 Construction of H105R mutant and plasmid propagation .................... 83 
5.2.3 Transformation into A. niger and selection for expression ................... 85 
5.2.4 Expression of the H105R mutant protein ................................................ 86 
5.2.5 Purification of the mutant protein ............................................................. 87 
5.3  Result and discussion ....................................................................................... 88 
5.3.1 Mutant DNA sequencing............................................................................ 88 
5.3.2 Transformaiton and expression result ..................................................... 88 
5.3.3 Purification ................................................................................................... 89 
5.4 Discussion ............................................................................................................ 90 
 
VI. DEGRADATION OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS 
DICLOFENAC AND NAPROXEN BY CHLOROPEROXIDASE ..................... 92 
 
REFERENCE ................................................................................................................137 
 
APPENDIX  ...................................................................................................................147 
 
VITA................................................................................................................................165 
 
 
 
 
 
 
 
 
xi 
 
LIST OF TABLES 
TABLE                                                                                                            PAGE 
 
Table 1.1 Conventional and advanced wastewater treatment and their removal 
range efficiency of pharmaceuticals. ..................................................................... 5 
 
Table 2.1 Accurate-Mass LC-Q-TOF-MS data for the identification of APAP     
and its metabolites. ................................................................................................ 24 
 
Table 2.2  Information of the proposed isomers........................................................ 29 
 
Table 3.1 The kinetic parameters of CBZ degradation catalyzed CPO. ............... 45 
 
Table 3.2 Accurate-Mass LC-Q-TOF-MS data for the identification of CBZ and  
its metabolites. ........................................................................................................ 46 
 
Table 3.3 The optimizer data of CM4, CM5 and CM7.............................................. 55 
 
Table 4.1 Accurate-Mass QTOF-LC/MS data for the identification of SMZ and   
its metabolites catalyzed in CPO-H2O2-Cl
- system. .......................................... 66 
 
Table 4.2 Possible identities of C12H14N4 (SM1)........................................................ 71 
 
Table 4.3 Accurate-Mass LC-Q-TOF-MS data for the identification of SMZ and  
its metabolites catalyzed in CPO-H2O2-Br
- system. .......................................... 76 
 
 
 
 
 
 
 
 
 
 
xii 
 
LIST OF FIGURES  
FIGURE                                                                                                         PAGE 
Figure 1.1 Fate of human and veterinary pharmaceuticals in the environment.  .... 2 
 
Figure 1.2 Crystal structure of CPO was presented by Pymol software  ................. 7 
Figure 1.3 Slice of CPO crystal structure with surface presentation........................ 8 
Figure 1.4 CPO active site presented by Pymol software (PDB entry 1CPO)    
with important amino acids in the distal pocket ................................................... 9 
 
Figure 1.5 The general mechanism of CPO catalyzed reation ............................... 12 
Figure 1.6 The oxidation of ABTS catalyzed by CPO .............................................. 13 
Figure 1.7 The dehalogenation of trihalophenol catalyzed by CPO ...................... 13 
Figure 1.8 The mechanism of CPO catalyzed one electron oxidation of 
fluorophenol............................................................................................................. 14 
 
Figure 1.9 Reactions catalyzed by CPO in phosphate buffer with chloride ions  . 16 
Figure 1.10 The chlorination of aromatic substrates catalyzed by CPO in 
phosphate buffer with chloride ions ..................................................................... 17 
 
Figure 2.1 UV-Vis Spectra of APAP , APAP with H2O2 and its metabolites at  
1min, 2.5min, and 4min ......................................................................................... 22 
 
Figure 2.2 The targeted MS/MS spectra of APAP and its metabolites .................. 27 
Figure 2.3 The relative area of each metabolite ........................................................ 28 
Figure 2.4 The proposed mechanism of the degradation of APAP catalyzed by 
CPO present by primary structure of each metabolites  ................................... 30 
 
Figure 2.5 Extracted  chromatogram of APAP and its metabolites detected by 
Triple-Quadrupole LC/MS/MS. ............................................................................. 31 
 
Figure 2.5 (Cont.)  Extracted  chromatogram of APAP and its metabolites 
detected by Triple-Quadrupole LC/MS/MS. ....................................................... 32 
 
Figure 3.1 UV-Vis Spectra of CBZ with H2O2 and its metabolites at 1min,    
2.5min and 4min ..................................................................................................... 40 
xiii 
 
Figure 3.2. The effect of chloride on the degradation of CBZ ................................. 42 
Figure 3.3 The effect of pH on CBZ degradation ...................................................... 43 
Figure 3.4 The effect of H2O2 concentration .............................................................. 44 
Figure 3.5 The effect of CBZ concentration ............................................................... 44 
Figure 3.6 The targeted MS/MS spectra of CBZ and its metabolites . ................... 48 
Figure 3.6 (Cont.).The targeted MS/MS spectra of CBZ and its metabolites  ....... 49 
Figure 3.7.  The percentage of each metabolites measured by compound area 50 
Figure 3.8 The area of metabolites with limited H2O2 at 1 min, 3 min and 5 min 
detected by Accurate-Mass LC-Q-TOF-MS ....................................................... 51 
 
Figure 3.9 The chromatograms of CBZ and its metabolites .................................... 53 
Figure 3.9 (Cont.) The chromatograms of CBZ and its metabolites  ...................... 54 
Figure 3.10 The proposed mechanism of the degradation of CBZ catalyzed by 
CPO. ......................................................................................................................... 57 
 
Figure 4.1 UV spectrum of SMZ degradation catalyzed by CPO ........................... 65 
Figure 4.2 (cont.) The targeted MS/MS spectra of APAP and its metabolites  ..... 69 
Figure 4.3 The percentage of each metabolites measured by compound area  .. 69 
Figure 4.4 The area of metabolites with limited H2O2 at 1 minute, 3 minutes     
and 5 minutes detected by Accurate-Mass LC-Q-TOF-MS............................. 71 
 
Figure 4.5. The chromatograms of CBZ and its metabolites ................................... 73 
Figure 4.5. (cont.) The chromatograms of CBZ and its metabolites  ...................... 74 
Figure 4.6. The proposed mechanism of the degradation of SMZ catalyzed by 
CPO-H2O2-Cl- system presented by primary structure of each metabolite  .. 75 
 
Figure 4.7 The percentage of the three metabolites measured by compound  
area........................................................................................................................... 76 
 
Figure 4.9.The mechanism of SMZ bromination catalyzed by CPO ...................... 78 
xiv 
 
Figure 5.1 The Proposed mechanism of His 105 in the cleavage of the     
peroxide O-O bond................................................................................................. 81 
 
Figure 5.2 The CPO expression vector pCPO3.1-AmdS......................................... 84 
Figure 5.3 DNA sequence of H105R mutant ............................................................. 88 
Figure 5.4 H105R mutant grown on 1.2 sorbitol selective agar plate  .................... 88 
Figure 5.5 The ABTS activity of H105R cultures since the second day of 
inoculation. Samples were run in triplicate......................................................... 89 
 
Figure 5.6 SDS-PAGE of mutated protein ................................................................. 90 
 
Figure 5.7 UV-Vis spectra of H105R mutant ............................................................. 90 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xv 
 
LIST OF ABBREVIATIONS AND ACRONYMS 
ABBREVIATION FULL NAME 
A Alanine 
ABTS 
2,20 
azinobis(3ethylbenzothiazoline6sulfonic 
acid) 
 
AMDOPH 1-acetyl-1-methyl-2-phenylhydrazide 
Amds A.nidulans acetamidase gene 
A. niger Aspergillus niger 
A. nidulans Aspergillus nidulans 
APAP 
N-acetyl-p-
aminophenol/Acetaminophen 
Asp Aspartic acid 
CBZ Carbamazepine 
CE Collision energy 
COSY Correlation spectroscopy 
CPO Chloroperoxidase 
DEAE Diethylaminoethanol 
DNA Deoxyribonucleic acid 
dNTP Deoxyribonucleotide 
Ε Extinction coefficient 
E/Glu Glutamic acid 
ee Enantiomeric excess 
xvi 
 
EE2 Estrogen 17α -ethinylestradiol 
FbF Find by Formula 
FIA Flow injection analysis 
His/H Histidine 
HPLC 
High performance liquid 
chromatography                       
LC-Q-TOF-MS                                                  
Liquid chromatography Quadrupole 
Time-of-Flight mass spectrometry 
 
LC-QQQ-MS 
Liquid chromatography Triple-
Quadrupole–mass spectrometry 
 
LDH Lactate dehydrogenase 
MCD 
MRM 
Monochlorodimedone 
Multiply reaction monitoring 
m/z Mass-to-charge ratio 
NAPQI N-acetyl-p-benzoquinone imine 
NMR 
Nuclear magnetic resonance 
spectroscopy 
NOE Nuclear overhauser effect 
NOESY 
Nuclear overhauser enhancement 
Spectroscopy 
 
OTC Over-the-counter 
R Arginine 
P450 Cytochrome P450 mono-oxygenase 
xvii 
 
PCR Polymerase chain reaction 
PglaA A. niger glucoamylase promoter 
Phe Phenylalanine 
ppm Parts per million 
RRHD Rapid Resolution High Definition 
Rz value Reinheitzahl value 
RT Retention time 
SDS-PAGE 
Sodium dodecyl sulfate polyacrylamide 
gel electrophoresis 
 
SMZ Sulfamethazine 
STP Sewage treatment plant 
TCC Thermostatted column compartment 
TtrpC 
A. nidulans anthranilate synthetase 
terminator 
UV Ultraviolet 
UV-Vis Ultraviolet-Visible 
 
 
 
 
 
 
 
 
1 
 
CHAPTER I. 
1.1 The occurrence of pharmaceutical pollutants in water  
Trace amounts of pharmaceuticals have been detected in water from 
nanograms per liter to micrograms per liter. Pharmaceuticals are chemicals that 
arise from natural sources or through artificial synthesis with the purpose to treat 
disease with highly specific biological targets. Even with lower concentration than 
regular contaminants, pharmaceuticals could still target biological organisms 
efficiently due to their properties. Pharmaceutical overdose or prolong exposure 
increase the potential risk of drug poisoning for both human and animals. Also, 
the hazards of pharmaceutical in the aquatic environment have been widely 
discussed in recent years. [1, 3] 
The annual consumption of prescribed drugs is about 100 tons in Germany, 
not including over-the-counter (OTC) drugs, so the actual total should be much 
more than the prescribed amounts. The pharmaceutical compounds that enter in 
the aquatic environment are mainly from human and veterinary medicines. The 
urine and feces from humans and animals affect the environment by different 
pathways. Human pharmaceuticals arise from their excretes and passed into 
sewage and are partially removed through the sewage treatment plant (STP) 
before entering the surface water that will goes through a series of process 
forming the drinking water we intake. Veterinary pharmaceuticals enter the 
environment similar to the human route where the animal’s excretes form 
contaminate manure which affect the soil and ground water by soil ferti lization. 
I. INTRODUCTION 
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Rainfall makes liquid manure and digested sludge flows into surface water. Soil 
and ground water may get contaminants from digest sludge applied in STP 
treatment. Another contaminated source is the disposal of pharmaceuticals in 
domestic waste without any previous treatment, leachates flow from the waste to 
landfill site, and continue to ground water and surface water. Finally, these 
detectable amount of pharmaceuticals reaches the drinking water sources. (Fig. 
1.1).[3, 4] 
 
  Figure 1.1 Fate of human and veterinary pharmaceuticals in the 
environment. [1, 4] 
 
The trace amouts of pharmaceuticals are not likely to have acute toxicity but 
have showed chronic ecotoxicity effects in animals. The lowest observed effect 
concentration (LOEC) of diclofenac on organ level for rainbow trout 
(Oncorhynchus mykiss) was in the same range as the detected concentration of 
the drug in wastewater.[5] The endocrine disrupter drugs have dramatically 
negtive effects on aquatic animal such as fathead minnows, with environmentally 
relevant concentrations (less than 1 ng/L) of estrogen 17α -ethinylestradiol (EE2), 
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showed adverse effects on fertilization and sex ratio and even secondary sex 
characteristics.[6, 7]  
The impact of  trace amount drugs in environment cannot be regardless, 
antibiotics resistant bacteria were detected in the surface water with highest 
average concentration of 78.31 ng/L.[8] Even in low concentration, antibotics can 
affect microorganism as signaling hormones, potentially threaten aquatic 
ecosystems and the public health[9] 
In drinking water, more than 10 drugs were detected frequently, the 
concentration of drug could achieve concentration as high as 270 ng/L (clofibric 
acid), and the concentration of drug metabolites could reach 0.9 ug/L (AMDOPH 
deriving from dimethylaminophenazone). Currently, there is no rountine test for 
monitoring the concentration of drug in drinking water. The risk of low 
concentrations of pharmaceuticals maybe minor, but with scarce information 
about the effects of chronic drug exposure, it still has the potential to affect 
human health negatively. The risk assessment of pharmaceutical in aquatic 
enviroment still needs to be evaluated in the future.[10-12] 
After 2006, the new compounds approved in Europe have to complete the 
assessment of enviromental toxicity and fate datasets, the older medicine are still 
need to consider of their persistence and harzards.[13] 
1.2 The treatment for removal of pharmaceuticals in water 
There are two types of wastewater treatment, conventional treatment and 
advanced treatment (Table 1.1). 
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Active sludge is the typical treatment of conventional treatment process, the 
removal efficiencies were varying regarding different factors such as temperature 
of degradation, and hydraulic retention time.[14] The biological fi ltration including 
the STP treatment, a process to remove contaminants in municipal wastewater,  
and produce environmental friendly metabolites, has been found to be insufficient 
to eliminate all persistent pharmaceutical residues. [15] The removal rates are 
inconstant due to the diversity of drug properties, for example, carbamazepine is 
resistant in STP but have different removal rate in active sludge.[16] 
Advanced treatments are widely investigated in the removing drugs in 
wastewater. Ozonation, microfiltration and ultrasound can achieve up to 100% 
degradation.  
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The application of ozonation with H2O2 is used in wastewater recycling for 
indirect potable reuse to degrade persistent organic pollutant. [1] However, the 
advanced treatments are needed to be further investigated considering the 
application possibility to individual pharmaceuticals, for instance, ozonation the 
high efficiency normally is activated by relatively high concentration of O3. The 
 
 
 
Table 1.1 Conventional and advanced wastewater treatment and their removal range efficiency of 
pharmaceuticals.   
 
 
 
a 
The removal efficiency is negative due to the calculation method, the hydraulic retention time is not 
considered. The influent sample and effluent sample are not absolutely related. And for 
carbamazepine, the negative removal efficiency is consistent, it is suggested the metabolites of 
carbamazepine can be converted to parent compound by enzyme activity in STP. [1] 
Wastewater treatment 
Removal range 
(%)
Activated sludge -193-100a
Biological filtration 6-71
Primary settling 3-45
Coagulation, filtration and settling 5-36
Sand filtration 0-99
Ozonation 1-100
Ozonation/ultrasound and sonocatalysis 23-45
Ozonation and catalytic ozonation >9-100
UV irradiation 29
Photolysis (UV/hydrogen peroxide) 52-100
Dark and light Fenton 80-100
UV/TiO2 >95
Biomembrane 23-99
Microfiltration and reverse osmosis 91-100
Reverse osmosis 62-97
Ultrasound 24-100
Conventional wastewater treatment 
Advanced wastewater treatment 
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oxidized products might be resistant to the ozonation and contain high acute 
toxicity. [17] Different economic and efficient wastewater treatments are required 
to be developed considering the complexity of pharmaceutical pollutions.  
1.3 The structure of CPO 
Chloroperoxidase (CPO) is a heme-containing glycoprotein secreted by the 
fungus Caldariomyces fumago. The molecular weight of CPO is approximately 
42,000 Daltons. Ferriprotoporphyrin IX is found to be its prosthetic group.[18] 
CPO consists of 299 amino acids, the tertiary structure of CPO mainly consists of 
eight alpha helical segments and a small beta pair (Fig. 1.2).[19] It has an active 
site similar to that of P450s and peroxidase. In comparison with P450s and 
peroxidase, the cysteine 29 is the heme ligand of CPO in the proximal pocket 
resembling P450s. The polar distal side is similar to peroxidase, whereas the 
acid-base catalyst in the active site of CPO responsible for the cleavage of the 
peroxide O-O bond is glutamic acid 183, instead of histidine which is typical in 
other peroxidase. [20] [21]  
There is a narrow channel connected the protein surface to the heme center, 
halogen ions are found to bind in the narrow channel, the halogen ion binding 
sties found suggested the pathway of halides from the protein surface to heme 
active center. In addition, there is a wide channel which suggest to be the binding 
site of bulky molecules, reaction such as oxidation, epoxidation might happen 
here  (Fig 1.3).[21] 
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In conventional heme peroxidases, histidine residue is the acid-base catalyst,  
whereas glutamic acid 108 (Glu 183) is the acid-base catalyst of CPO. Generally 
for heme peroxidase, the catalyst residue interact with another amino acid to 
cleave the peroxide bond. In CPO, the residue suggested to interact with Glu183 
assisting in the formation of compound I is His105. 
In conventional heme peroxidases, histidine residue is the acid-base catalyst,  
whereas glutamic acid 108 (Glu 183) is the acid-base catalyst of CPO. Generally 
Figure 1.2 Crystal structure of CPO was presented by Pymol software, the protein 
data bank (PDB; http://www.pdb.org) entry 1CPO was used. Heme prophyrin was 
depicted as red color, located in the center of protein. [20] 
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for heme peroxidase, the catalyst residue interact with another amino acid to 
cleave the peroxide bond. In CPO, the residue suggested to interact with Glu183 
assisting in the formation of compound I is histidine105. 
His 105 is hydrogen bonded to Glu 183 and Asp 106, the hydrogen bondings 
facilites the cleavage of peroxide bond and positioning Glu 183 properly with 
relation to heme center during the catalyzation. [20, 21, 23] Two pheylalanine 
residues (Phe 103 and Phe 186) are close to the heme iron and thought to 
interact with hydrophobic substrate and control the substrate to access the heme 
center (Fig 1.4). [21] There is also other result that occurs because of the 
Figure 1.3 Slice of CPO crystal structure with surface presentation. Heme is depicted in magenta, 
narrow channel and wide channel are marked by arrow. Yellow sphere presents bromide and 
blue sphere presents iodide. The binding sites of halide are labeled by numbers (1 -3) in red color. 
[22] 
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modification of histidine residues, suggested His 105 affected epoxidation and 
peroxide dismutations but not decreased peroxidation rate.[24] CPO might have 
multiply reactive sites regarding the same reaction, and the role of H105 still 
needs to be further investigated by other techniques to unravel the  mechanism 
of CPO.  
His 105 is hydrogen bonded to Glu 183 and Asp 106, the hydrogen bondings 
facilites the cleavage of peroxide bond and positioning Glu 183 properly within 
heme center during the catalyzation. [20, 21, 23] Two pheylalanine residues (Phe 
103 and Phe 186) are close to the heme iron and thought to interact with 
hydrophobic substrate and control the substrate to access the heme center (Fig 
1.4). [21] There is also other result based on the modificatiion of histidine 
residues, suggested His 105 affected epoxidation and peroxide dismutations but 
not decreased peroxidation rate.[24] CPO might have multiply reactive sites for 
Figure 1.4 CPO active site presented by Pymol software (PDB entry 1CPO) with important amino 
acids in the distal pocket. Heme is depicted in grey. His 105 was proposed to form hydrogen 
bonds with Glu 183 and Asp 106, conferring the proper position of Glu183 and the orientation to 
form compound I.Phe 103 and Phe 186 were observed to be close to heme center, might control 
the access of substrate by polarity. [21] 
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the same reaction, and the role of H105 still needs to be further investigated by 
other techniques to unravel the  mechanism of CPO.  
1.4 The mechanism of CPO catalyzed reactions 
The complex structure of the CPO active site associates with the multiple 
functions of CPO. The general catalytic cycle of CPO starts from the resting state 
of the enzyme, the native ferric center binds by H2O2 at the heme iron and to 
form the oxo-ferryl cation radical intermediate called compound I, during the 
reaction, two electrons from the heme center are transferred to H2O2 and cleaved 
the O-O bond, producing H2O.  Compound I is involved in different types of 
chemical reactions. In the dismutation pathway, compound I will continue to react 
with H2O2 to generate O2 and H2O, and be reduced back to its resting state. In 
the P450 pathway, the organic substrate (RH) is hydroxylated and compound I is 
reduced back to ferric resting state. 
Another pathway is peroxidation by forming another reactive intermediate 
compound II, the oxo-ferryl intermediate. During the process, one electron from 
compound I is transferred to an organic molecule (AH), converting AH to the 
radical molecule (A.). [25, 26] Electron is transferred to the organic substrate from 
compound II, and CPO returns to the resting state.[27] In general, another major 
pathway of compound I  is halogenation by interacting with halide (X) to form 
compound X, a ferric intermediate. Compound X will halogenate organic 
substrate (AH) and generate hydroxyl ion (OH-), returns back to its resting state 
(Fig. 1.5). 
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Compound I with strong oxidizing ability is also proposed to generate 
hypochlorous acid / hypobromous acid, or Cl2 / Br2 as the active intermediates in 
the oxidative chlorination. They are presumed to diffuse into the medium and to 
oxidize the substrate externally or react with substrates within the active sites. 
[28-32] The chlorination mechanism of CPO will be further discussed and 
confirmed in my research.  
1.5 CPO catalyzed reactions 
CPO catalyzes two major types of oxidations; they are two one-electron 
oxidations as catalyzed by most peroxidases and two-electron oxidations which 
are rare for conventional peroxidases.  
1.5.1 One-electron oxidations 
The one electron oxidations of CPO include peroxidation and dehalogenation 
and polymeration driven by radical. [33, 34] The typical peroxidation of CPO is 
the oxidation of 2,2'-azinobis-3-ethylbenzothiazoline-6-sulfonic acid (ABTS), it is 
used as ABTS assay to measure the peroxidase activity of CPO / mutant CPO 
(Fig 1.6). [35] 
Dehalogenation was found in trihalophenols and fluorophenols (Fig 1.7) 
According to the general mechanism, fluoride is not involved in halogenation 
catalyzed by CPO, whereas in dehalogenation, fluoride of substrate is reacted. 
Both reactions show the potential application of CPO in environmental pollutant 
treatment. In the defluorination of fluorophenols, dimers and trimers were 
generated in one electron oxidation. [33, 34]  The function of polymerization 
showed in some other peroxdase is also found in CPO catalyzed reaction. [34, 35] 
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Figure 1.5 The general mechanism of CPO catalyzed reation. AH presents the substrate, the oval 
presents the heme; compound I and II present the ferryl intermediates; X presents halogen atom 
(except F
-
).[29] 
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Dehalogenation was found in trihalophenols (Fig. 1.7)and fluorophenols (Fig 
1.8) According to the general mechanism, fluoride is not involved in halogenation 
catalyzed by CPO, whereas in dehalogenation fluoride of substrate reacted. Both 
reactions show the potential application of CPO in environmental pollutant 
treatment. In the defluorination of fluorophenols, dimers and trimers were 
generated in one electron oxidation. [33, 34]  The function of polymerization 
showed in some other peroxdase is also found in CPO catalyzed reaction. [34, 35]  
 
 
 
Figure 1.6 The oxidation of ABTS catalyzed by CPO.[36] 
Figure 1.7 The dehalogenation of trihalophenol catalyzed by CPO.[33] 
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Figure 1.8 The mechanism of CPO catalyzed one electron oxidation of fluorophenol.[34] 
 
1.5.2 Two-electron oxidations 
The two-electron oxidations includes halogenation and oxygen transfer as the major 
reactions. The significant function of CPO was found as the chlorination of 
monochlorodimedone (MCD), this reaction is routinely used as MCD assay to measure 
the chlorination activity of CPO /mutant CPO (Fig 1.8a).Other halogenation can also be 
carried out by bromide or iodide ions.[37] There are other substrates catalyzed by CPO 
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in the halogenation, such as phenol. (Fig .1.9), 1,3-cyclopentanedione  and  alkenes (Fig 
1.8b) [37-39] The oxidative chlorination catalyzed by CPO for halogenated phenols or 
phenols typically generated different isomers, which will be discussed in my research. 
The other important two-electron oxidation consists of epoxidation with 
enantioselectivity, hydroxylation examples are showed in figure 1.8c [40] 
1.6 The application tendency of CPO 
The structural and functional features of CPO are suggested its potential as industrial 
and environmental biocatalysts, the catalyzation only needs relatively low concentration 
H2O2 as cofactor which is economic and safe in application. 
To synthesize biological or pharmaceutical chemicals, CPO is an ideal candidate. 
The enantioselectivity of oxidation catalyzed by CPO was relatively high regarding the 
reaction of oxidizing primary alcohols to the corresponding aldehydes, and result could 
be improved with lowered temperature and at fixed pH to achieve a higher enatiomeric 
purities (ee). In addition, tert-butyl hydroperoxide was used instead of hydrogen 
peroxide.[41] 
The fate and mechanism of azo dye degradation catalyzed by CPO was investigated 
and the high efficiency of the reaction implied the possibility of CPO application in the 
large scale wastewater treatment.[28, 42] 
Recently, the degradation of sulfamethoxazole was investigated by utilizing CPO 
with active sludge to increase the drug degradation efficiency. [43] The potential of CPO 
application in degrading different pharmaceuticals will be analyzed in my dissertation. 
To stabilize CPO and increase the recyclability of the enzyme the catalyst was 
conjugated to poly (hydroxypropyl methacrylate-co-polyethyleneglycole methacrylate) 
membranes, which enhanced the storage and thermal stability compared to the free 
CPO. Immobilization of CPO will be one tendency of CPO application, a research will be 
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done to introduce CPO to the large scale application.  
 
 
 
 
 
 
Figure 1.9 Reactions catalyzed by CPO in phosphate buffer with chloride ions. (a) The 
chlorination of MCD catalyzed by CPO.[38] (b) The examples of halogenation by ,3-
cyclopentanedione and  alkenes.[38, 39] (c) The typical examples of epoxidation and 
hydroxylation catalyzed by CPO with the yields and enatiomeric purities (ee).[41] 
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Figure 1.10 The chlorination of aromatic substrates catalyzed by CPO in phosphate buffer with 
chloride ions.[39] 
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CHAPTER II. 
II. CPO-CATALYZED CHLORINATION AND POLYMERIZATION OF 
ACETAMINOPHEN 
2.1. Background 
Acetaminophen (N-acetyl-p-aminophenol, APAP), also known as 
paracetamol, is an active ingredient in over-the counter medicines and widely 
used for relieving fever and pain. The production of APAP was estimated to be in 
the ki loton level in the USA per year.[44] Overdose causes serious liver damage 
because of the formation of N-acetyl-p-benzoquinone imine (NAPQI).[45] APAP 
is ubiquitous in the natural environment,  detected as 1.89 µg/L in ground water 
in the U.S.A[46] Occurrence of APAP as a contaminant in wastewater and 
drinking water increased the risk of human health and investigations of 
biodegradation of APAP.[47, 48] 
Bioremediation catalyzed by CPO is a potential treatment as a consequence 
of its environmental friendliness and low cost investment. The efficiency of APAP 
degradation catalyzed by CPO would be investigated, the metabolites and 
pathway would be proposed in this experiment. 
2.2 Experimental Procedure 
2.2.1 Material 
Chloroperoxidase (CPO) is a heme-containing glycoprotein secreted by the 
marine fungus Caldariomyces fumago. The isolation of CPO proposed in this 
study was a modification of the protocol reported by Morris and Hager[18] where 
acetone was used as precipitating agent instead of ethanol as the fractionation 
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solvent. CPO with Rz =1.45 (Rz is purity standard defined as A398/A280 = 1.44 for 
pure enzyme) was applied in all reactions. All solvents were HPLC grade or 
Optima® LC/MS grade, purchased from Thermo Fisher Scientific Inc. (Waltham, 
MA, USA). Water was produced by using a Milli-Q®  Biocel™ Ultra-Pure water 
purification system equipped with 0.22 µM membrane filter cartridge (EMD 
Millipore, Billerica, MA, USA), and an organic removal cartridge (Evoqua Water 
Technologies, Lowell, MA, USA).  
 2.2.2 UV-Visible spectrophotometry 
A VARIAN UV-Vis spectrophotometer (Cary 200 Bio) was used to collect the 
UV spectra of the degradation products. The drug solution was scanned by 
dissolving 0.11 mM APAP in 100 mM KH2PO4 buffer with 20 mM KCl at pH 2.75. 
The same solution was monitored after mixed with 0.55mM H2O2. The reaction 
was initiated with the addition of 5 nM CPO and UV-Vis spectrum was recorded 
for the reaction time: 1 minute, 2.5 minutes, and 4 minutes. 
2.2.3 Liquid chromatography and mass spectrometry 
2.2.3.1 Sample preparation 
To investigate the degradation efficiency, 62.56 µM APAP was reacted with 
321.56 µM H2O2 and 0.43 nM CPO for 1 hour at room temperature. Mixture was 
centrifuged at 3,000 g in Centriprep® centrifugal filter unit with a 30,000 Dalton 
cut-off membrane (EMD Millipore, Billerica, MA, USA). The yielded products was 
collected after centrifuged for 1min. Ethyl acetate was used to extract the filtrate 
while shaking vigorously, and the supernatant was evaporated to dryness by 
using nitrogen gas. The dried metabolites were dissolved in H2O /methanol (95:5 
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v/v) to make the final concentration 1 mg/L (ppm). Sample was stored at -20 °C 
in a freezer or immediately run in the LC-Q-TOF-MS mass spectrometer system. 
A low concentration of CPO and H2O2 reaction sample was prepared as 
follows: 6.86 µM H2O2 was added directly to Centriprep
® centrifugal filter unit with 
the same membrane size as described above.  Then 66.20 µM APAP were 
added, catalyzed by the addition of 1.28 nM CPO in the 100 mM phosphate 
buffer with 20 mM KCl for 3 minutes and 5 minutes. The experiments were run in 
triplicate. The dried metabolites were dissolved in H2O/methanol (95:5 v/v) to 
make an approximate concentration of 1 mg/L (ppm), and detected by LC-Q-
TOF-MS system immediately. 
The high concentration of APAP sample was prepared by mixing 413 µM 
APAP with 2 mM H2O2, catalyzed by 2 nM CPO for 35 minutes at room 
temperature. The extraction was carried out by ethyl acetate, and the organic 
layer was dried by nitrogen gas. Metabolites were dissolved in 1.5 mL 
H2O/methanol (95:5 v/v) to make an approximate final concentration of 5 mg/L 
(ppm). The sample was filtrated through 0.22 µM polyethersulfone syringe filter. 
The sample was stored in a freezer at -20°C, detected both in Q-TOF-LC-MS 
system and Triple-quadrupole LC-MS/MS system. 
2.2.3.2 Instrumentation and chromatographic separation 
The Agilent 1290 Infinity UPLC system coupled with Agilent 6530 Q-TOF 
mass spectrometer was used for the chromatographic separation and 
identification of the metabolites. The Agilent MassHunter Data Acquisition 
Software (rev. B0.06.00) was used to control the UPLC and the mass 
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spectrometer. Mass Hunter Qualitative Data Analysis Software (Rev. B.07.00 was 
used for data mining and identification. An Agilent ZORBAX Eclipse plus C18 
Rapid Resolution High Definition (RRHD) column (100 mm×1.8 µm) was applied, 
the column temperature was set at 30 °C via a thermostatted column 
compartment (TCC).  An infinity 1290 automatic injector was used to Inject 1 µL 
(microliter) of the sample to the column. A flow rate of 0.4 mL/min was used and 
a aqueous mobile phase A consisting of water with 5 mM ammonium formate 
with 0.1% formic acid and the organic mobile phase B consisting of acetonitrile 
with 0.1% formic acid. The optimized chromatographic gradient was at 0 minute, 
95% A and 5% B and B increased linearly to 95% over 8 minutes, this gradient 
was maintained for 1 minute. The positive ionization mode was applied during all 
experiments. 
In full scan MS mode, the accurate mass data of the molecular ions were 
processed through the Agilent MassHunter Qualitative Analysis software. The 
collected retention times and confirmed formulas of every metabolite were 
applied in targeted MS/MS mode to identify metabolites information.  
Additionally an Agilent 6460 Triple-Quadrupole LC/MS/MS mass spectrometer 
was used to increase the detection sensitivity of the isolated metabolites that 
were initially identified by the LC-QTOF mass spectrometer. The same column 
and elution program previously used in the LC-QTOF was employed in the LC-
QQQ-MS system.  
2.2.3.3. Data Mining and Database development. 
To create a database of all metabolites with optimized parameters, several 
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search algorithms were used in Mass Hunter Qualitative Data Analysis Software.  
One of this algorithms was Find by Formula (FbF) which allow the search of a 
compound using its molecular formula.  The search could include not only the 
formation of the molecular ion [M+H]+ but also  the formation of adducts (like 
ammonium or sodium adducts) typically observed under the ionization conditions 
in electrospray. The samples were initially infused into the system by flow 
injection analysis (FIA) and later subjected to chromatography.  Additional work 
was performed by LC-QQQ-MS detection for those metabolites present at low 
levels of concentration. 
2.3 Result and discussion 
2.3.1 UV-Vis study of CPO-catalyzed degradation of APAP 
 
The UV-Vis Spectrum of APAP (0.11 mM) were scanned in 100 mM KH2PO4 
Figure 2.1 UV-Vis Spectra of APAP , APAP with H2O2 and its metabolites at 1min, 2.5min, 
and 4min. 
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buffer with 20 mM KCl at pH 2.75. The Spectrum of APAP showed a strong 
absorption at 242 nm. After mixed with 0.55 mM H2O2, the absorption curve 
increased slightly due to absorbance of H2O2. 1 minute after addition of 5 nM 
CPO, the 477 nm absorption decreased, and increased at 4 min. The absorption 
at 218 increased after 1 min, and stopped increasing at 2.5 min (Fig. 2.1). The 
absorption of metabolites covered the absorption of original drug, which made 
the detection of kinetic parameter of APAP degradation catalyzed by CPO 
impossible.    
The same reaction was carried out under the same condition except for the 
absence of chloride ion (KCl) in phosphate buffer. Without KCl, the absorbance 
did not change after the addition of CPO. Chlorine ion is necessary in the 
degradation of APAP in CPO-H2O2-Cl
- system. 
2.3.2 LC-Q-TOF- MS 
To investigate the degradation efficiency of APAP in CPO-H2O2-Cl
- system, 
62.56 µM APAP was reacted with H2O2 (321.56 µM) and CPO (0.43 nM) for 1 
hour, the sample was analyzed by LC-Q-TOF-MS, APAP was not observed, the 
degradation efficiency by low concentration of CPO could achieved 100%, 
suggesting the potential of the application of CPO in large-scale waste water 
treatment. 
There were 7 APAP metabolites (coded from AM1 to AM7) confirmed by 
different retention times and accurate mass-to-charge ratios (m/z). The elemental 
formula, retention time, the relative mass difference between the observed mass 
and the mass of the target compound (in parts per million), and the difference 
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between the observed mass and the mass of target compound (in milliDaltons) 
were collected (Table 2.1). 
 
The mass spectrum of each individual metabolite found (7 in total) are 
included in Appendix I.  The mass accuracy of the standard drug (APAP) was 
calculated and the values ranged between 0.37 ppm and 9.75 ppm. The relative 
mass differences of metabolites were between 0.59 ppm and 3.23ppm. The 
mass differences of all compounds were less than 1.1 mDa. This method was 
proved to be efficient for determination of the metabolites of APAP. 
Dimer (AM2) and Trimer (AM6) were formed, their chlorinated products were 
observed as AM3, AM7 respectively. For chlorinated metabolites, the isotope 
peaks were detected as the conformation of addition of chlorine atom. For AM1, 
AM3 and AM7, the two major peaks of each spectra separated by 2 m/z units 
and peak heights are in the ratio of 3:1, proved these molecules contain one 
chlorine atom. For AM4 and AM5, there were 3 lines in the molecular ion region 
Table 2.1 Accurate-Mass LC-Q-TOF-MS data for the identification of APAP and its 
metabolites. 
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(M+, M+2 and M+4) with gaps of 2 m/z units between them, and with peak 
heights in the ratio of 9:6:1, it was confirmed that both compounds contain 2 
chlorines. 
 The structures of each metabolite were confirmed in targeted MS/MS by 
retention time and fragment ions (Fig. 2.2). The concentration of AM7 was low, 
the majority form of AM7 was [M+Na]+ (472.1453 m/z).  
2.3.3 Triple-quadruple LC/MS/MS 
Agilent Technologies 6460 Triple-quadrupole LC/MS/MS in multiply reaction 
monitoring (MRM) mode was applied in investigation of metabolites of APAP. 
Data were analyzed with  Agilent MassHunter Qualitative Analysis software. After 
the formula of metabolites was confirmed by LC-Q-TOF-MS,  
Individual metabolites were assessed with a more sensitive analytical technique 
(LCQQQ-MS). For example, AM1 showed one solid peak with a mass 
corresponding to m/z 186.03 in Q-TOF both in full scan mode. The use of an 
MRM method in Triple-quadrupole LC/MS/MS, two peaks were clearly eluted at 
different retention times. For detection of isomers in complex biological matrix, 
Triple-quadrupole shows excellent sensitivity and selectivity for target 
compounds by fi ltering out the purities with the same molecular weight as 
targeted products.  
The specific parameters, including optimized fragmentor voltage and collision 
energy (CE) for different MRM transition has been determined by flow injection 
analysis without column (FIA) with MassHunter Optimizer software (Appendix II).  
Routine MRM mode, more than one MRM transition per compound is used to   
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avoid false-positive results, two transitions are monitored for one compound in 
most cases. 
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C8H7Cl2NO2 (AM4)                                    C16H14Cl2N2O4 (AM5) 
 
C16H16N2O4  (AM2)                          C16H15ClN2O4 (AM3) 
C24H23N3O6 (AM6)                                               C24H22ClN3O6 (AM7) 
Figure 2.2 The targeted MS/MS spectra of APAP and its metabolites. 
C8H9NO2  (APAP)                               C8H8ClNO2 (AM1) 
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The relative area in chromatogram was used to measure the abundance of 
each metabolite (Fig. 2.3a). AM1 and AM2 were the major product. To investigate 
the mechanism of the degradation, limited concentration of H2O2 was added to 
the reaction, the ratio of APAP and H2O2 was 10:1. At first 3 minutes, the 
formation of AM2 was predominant within 5 minutes. The proportional area was 
consistent with the degradation by higher concentration H2O2. (Fig. 2.3b). There 
were no other metabolites observed at the first reaction stage, suggesting the 
mechanism that AM3, AM4, AM5, AM6 and AM7 were formed from AM1 and AM2 
(Figd2.4). 
 
The different elution times of the same formula was considered as isomers. In 
addition, the exist of isomers could also be suggested with distinctive product 
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Figure 2.3 The relative area of each metabolite. (a) In high concentrated sample, the area of 
AM1 was set as 100%, compared with AM1, AM2 -AM6 is 96.94%, 48.08%, 18.12%, 8.93%, 
respectively. The area of AM7 was only 0.06%.  (b) The area of AM1 at 3min was  5602 with 
error is 4879,  at 5min increases dramatically to 50800 with error 2103; AM2 is 63866 at 
3min with error 1452, and 57423 at 5min with error 1201  .Each experiment  was run in 
triplicate. 
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ions by the same fragmentor voltage at different retention time (Table 2.2).  The 
concentration of AM7 is too low to detect the different elution time of isomers. 
The other 6 metabolites showed a good resolution.  
To consider the relatively low concentration isomers, all optimized MRM 
transitions were loaded into the MassHunter Acquisition software for performing 
data analysis. The chromatograph of each formula was extracted by Agilent 
MassHunter Qualitative Analysis software with the proposed structures, the first 
structure shown on the chromatogram is the proposed primary structure with 
highest concentration (Fig 2.5.)   
 
  
 
 
Table 2.2  Information of the proposed isomers (RT presents retention time). 
Code RT (min) Area Share transitions Specific transitions
AM1-1 4.220 517761 53, 80, 144 
AM1-2 3.923 34544
AM2-1 3.664 812260 43, 127, 154 , 172,  182, 200, 217
AM2-2 4.292 64986
AM3-1 4.405 223747 142, 170, 198, 199,215, 257, 293,317
AM3-2 4.890 66386 124, 142, 199, 293, 317
AM3-3 9.397 111378
AM4-1 5.090 77208
AM4-2 4.776 4866
AM5-1 5.423 375540 218, 326
AM5-2 5.704 104506 218,326
AM5-3 4.943 71328 326
AM5-4 5.551 54057 326
AM6-1 9.714 36531 191, 253, 433
AM6-2 9.046 5142 71
AM6-3 8.480 5122 71
AM6-4 8.838 2809 71
43
43, 52, 79, 143, 178
57
43,54, 73,81, 82, 109, 168
108, 259, 283
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Figure 2.4 The proposed mechanism of the degradation of APAP catalyzed by CPO 
present by primary structure of each metabolites. 
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2.4 Discussion 
NAPQI is the significant hepatotoxicity intermediate product of APAP 
catalyzed by the cytochrome P450 enzyme.[49] CPO shares the similar structure 
of P450 in proximal heme iron thiolate ligand,[50] but obviously, for catalyzing the 
degradation of APAP, the function of chlorination and dimerization is preferred 
instead of oxidation. For degradation of APAP, CPO-H2O2-Cl
- system works 
differently from hypochlorite and P450, suggesting the specific ability of 
detoxification of APAP. AM1 is a chlorinated APAP product, previously AM1-1 was 
reported in nitration processes of acetaminophen in nitrifying activated sludge as 
a low concentration transformation product. [51] 
AM1-1 and AM4-1 are two ring chlorination metabolites of APAP. They were 
detected after APAP (10 µmol/L) reacted with hypochlorite (57 µmol/L) for 1 hour, 
88% APAP was transformed. The approximate concentration of two chlorinated 
metabolites was 7% of the initial APAP. The concentration was relatively low 
when compared with the experiment catalyzed by CPO. When APAP mixed with 
hypochlorite, two toxic quinoidal oxidation products were produced, 1,4-
benzoquinone and N-acetyl-p-benzoquinone imine (NAPQI) accounted for 25% 
and 1.5% of the initial acetaminophen concentration, respectively, which were not 
detected in CPO-H2O2-Cl
- system. Evaluation on the toxicity of the final products 
indicated that, CPO has the potential application in the purification of waste water 
when compared with regular chlorine disinfection systems. 
AM4 was two electron-withdrawing chlorine substituent, compared the LDH 
leakage in hepatocytes with APAP, the LDH leakage was 36%, and APAP was 
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about 51%. Other analogues at the 3,5 positions were tested (R=-F, -Br, and -I), 
the value were from 42% to 15%. Besides, these halogenated products 
decreased the inhibitory potency towards cyclooxygenase, showed the deceased 
function of drug, both evidences implied that the halogenation of APAP in waste 
water by CPO-H2O2-Cl
- system could decrease the cytotoxicity and drug effect in 
human body.[49] 
Dimer (AM2), trimer (AM6) and their chlorinated products (AM3, AM5, and 
AM7) were identified in CPO catalyzed reaction. Both dimer and trimer were 
detected in the horseradish peroxidase catalyzed polymerization of APAP, there 
were two dimers and three trimers detected by 500-MHz proton magnetic 
resonance spectroscopy.[35] The number of polymerized isomers generated by 
CPO catalyzed reaction were consistent with horseradish peroxidase catalyzed 
polymerization, and we proposed the same structure of each isomers. In the 
polymerization by horseradish peroxidase, the polymers formed primarily through 
a covalent bond between carbons ortho to the hydroxyl group due to the high 
unpaired electron density, and to a lesser extent, between the carbon ortho to the 
hydroxyl group and the amino group of another APAP molecule, as the isomer 
ratios observed from chromatograms of CPO catalyzed reaction.  
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CHAPTER III. 
3.1 Background 
Carbamazepine (CBZ) is widely used in the treatment of epilepsy, trigeminal 
neuralgia and bipolar disorder. [52] CBZ has been studied as persistent 
anthropogenic pollutant which is detectable in surface water, ground water, and 
even in drinking water. In Germany, the annual consumption of CBZ was over 80 
tons, and the concentrations detected were 6.3 µg/L in STP effluent, 26 ng/L in 
urban groundwater, 762 ng/L in surface water, 1640 ng/L in raw sewage, and 65-
86 ng/L in tap water.[4, 7, 53] In other European surface water, the highest 
concentration was reported from 110-800 ng/L. [1] In addition, 420 ng/L CBZ was 
detected in the ground water used for public drinking water supply in USA. [46]  
10 µg/L CBZ showed obviously cytotoxic to gill cell of fish.[54] It was reported 
that CBZ administration caused tumors in rats for 2 years drug treatment, and 
reduced the humoral and cellular immune responses, and induced spleen 
cellularity.[55, 56] Therefore, Long time exposure to CBZ in drinking water is a 
potential risk to human health. 
The common water treatment is effective to degrade CBZ, even with some 
new biodegradation method was investigated such as biodegradation by algea, 
fungus, phtocatalysis, etc. [4, 57-59] CPO has the potential to apply in 
degradation of CBZ due to its high efficiency (catalyzed within minutes), less 
expensive (work with nanomolar level enzyme) and its stability in acidic 
wastewater (pH 2.0-5.0). The CBZ degradation efficiency in water, the kinetic 
III. CPO-CATALYZED DEGRADATION OF CARBAMAZEPINE 
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parameters and the products of CBZ catalyzed by CPO was investigated in this 
experiment. 
The aim of this experiment was to investigate the potential application of CPO 
in the degradation of CBZ. The efficiency of CPO in the degradation of CBZ was 
measured. The operating conditions including the concentration of Cl-, reaction 
buffer pH, and the concentration of H2O2 was optimized, and under the optimized 
conditions, the enzyme kinetic and degradation pathway was studied. 
3.2 Experimental Procedure 
3.2.1 Material 
All material and chemicals used were the same as described in section 2.2.1. 
3.2.2 UV-Visible spectrophotometry 
3.2.2.1 UV-Vis spectrum of degradation 
A VARIAN UV-Vis spectrophotometer (Cary 200 Bio) was used to collect the 
UV spectra of the degradation products. The drug solution was scanned by 
dissolving 0.07 mM CBZ in 100 mM KH2PO4 buffer with 20 mM KCl at pH 2.75. 
The same solution was monitored after mixed with0.35mM H2O2. UV spectra 
were recorded after the addition of 5 nM CPO for 1minute, 2.5 minutes and 4 
minutes. The degradation efficiency was calculated according to Equation (1) 
Efficiency (%) = 
𝐴0−𝐴𝑡
𝐴0
× 100                                                                   (1) 
3.2.2.2 Effect of diverse parameters on CPO degradation 
The effect of the concentration of chloride was investigated. Degradation was 
carried out in 100 mM phosphate buffer at pH 3.0 with 0.07 mM CBZ and 0.07 
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mM H2O2, concentration of chloride was increased from 0 to 20 mM, 285 nm 
wavelength was monitored immediately after 2.5 nM CPO was added. 
The degradation rate at pH range of 2.0 to 5.0 was investigated to probe the 
effect of pH on CPO catalyzed reaction. The reaction was carried out in 100 mM 
phosphate buffer with 20 mM KCl, 0.07 mM CBZ, and 0.07 mM H2O2. H3PO4 and 
KOH were used to adjust pH, 285 nm wavelength was monitored immediately 
after  the addition of 2.5 nM CPO. The calculated time was from 0.2 to 0.4 
minute.  
The degradation rate of CBZ was determined by different concentration of 
hydrogen peroxide from 0.07-0.71 mM in 100 mM phosphate buffer with 20 mM 
KCl and 0.07 mM CBZ at pH 3.0. 285 nm wavelenth was monitored immediately 
after the addition of 5 nM CPO. Rate from 0.1mintute to 03 minute was 
calculated as degradation rate. 
It was assumed that the degradation would follow Michaelis-Menten kinetics, 
and the Lineweaver-Burk plot Equation was used to calculate Michaelis-Menten 
constant (Km) and maximum reaction rate (Vmax) (2), where the [𝑆] presents the 
concentration of substrate (CBZ), V presents the initial reaction rate, the rate was 
calculated by monitoring at 285 nm absorbance from 0.1-0.2 minute. The 
reaction was carried out in 100 mM concentration of KH2PO4 buffer with 20 mM 
KCl at pH 2.75, the concentration of CBZ was varying from 0.02 mM to 0.11 mM. 
UV was started to monitor immediately after adding 0.35 mM H2O2. 
1
𝑉
=
𝐾𝑚
𝑉𝑚𝑎𝑥
×
1
[𝑆]
+
1
𝑉𝑚𝑎𝑥
                                                                           (2) 
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The turnover number (kcat) was obtained by the equation (3), calculated from the 
maximum reaction rate (Vmax) and the concentration of CPO (E0).  
      𝑉𝑚𝑎𝑥 = 𝑘𝑐𝑎𝑡[𝐸0]                                                               (3) 
All experiments were triplicated and data reported were mean values of three 
independent measurements with standard deviation. 
3.2.3 Liquid chromatography and mass spectroscopy  
3.2.3.1 Sample preparation 
To investigate the degradation efficiency, CBZ was dissolved in methanol to 
make stock solution (21.19 mM), 10.59 µM (2.5 mg/L) CBZ was reacted with 
107.19 µM H2O2 and 2.9 nM CPO for 10 minutes at room temperature. Mixture 
was centrifuged at 3,000 g in Centriprep® centrifugal filter unit with 30,000 Dalton 
cut-off membrane (EMD Millipore, Billerica, MA, USA). The filtrate was collected 
after centrifuged for 1min. Ethyl acetate was used to extract the filtrate while 
shaking vigorously. The remove the organic solvent, nitrogen gas purge was 
applied to dry the sample. The dried residues were dissolved in H2O /methanol 
(95:5 v/v) to make the final concentration approximate 1 mg/L (ppm). The sample 
was stored at -20 ℃ in a freezer, or immediately run in LC-Q-TOF-MS mass 
spectrometer system. 
To detect all metabolites of CBZ, CBZ was dissolved in methanol to make 
stock solution (21.19 mM), a high concentration of CBZ sample was prepared by 
mixing 62.56 µM (14.8 mg/L) CBZ with 0.4 nM CPO, H2O2 stock solution (41.16 
mM) was added to reaction system at 56.5 µL/minute to make the final 
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concentration of H2O2 up to  316.56 µM. The total reaction time was 55 minutes. 
The solution was extracted by ethyl acetate, and the supernatant was evaporated 
by using nitrogen gas. Metabolites were dissolved in 2.0 mL H2O/methanol (95:5 
v/v) to make the final concentration approximately 5 mg/mL (ppm). The sample 
was centrifuge at 1200 g for 10 minutes, 1.5 mL supernatant was removed by 
syringe. Filtration was applied by using 0.22 µM polyethersulfone syringe filter. 
The sample was stored at -20 ℃ in freezer, detected both in LC-Q-TOF/MS 
system and Triple-Quadrupole LC/MS/MS system.  
To investigate the mechanism of degradation, samples were prepared with 
low concentration of H2O2. 6.86 µM H2O2 was added directly to Centriprep
® 
centrifugal filter unit (30,000 Dalton) with 42.28 µM CBZ, catalyzed by 1.3 nM 
CPO in the 100 mM phosphate buffer with 20 mM KCl for 1 minute, 3 minutes 
and 5 minutes, filter units were centrifuged at 3000g for 1min at room 
temperature, and extracted the filtrate by ethyl acetate, purged the organic phase 
with nitrogen gas to dryness. The dried metabolites were dissolved in 
H2O/methanol (95:5 v/v) to make the final concentration approximate 1 mg/L 
(ppm), and detected by LC-Q-TOF-MS system immediately. Experiments were 
run in duplicate.   
3.2.3.2 Instrumentation and chromatographic separation 
The instrumentation and chromatographic separation were the same as in 
section 2.2.3.2. 
3.2.3.3. Data Mining and Database development 
The data Mining and Database development were the same as in section 
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2.2.3.3. 
3.3 Result and discussion 
3.3.1 UV-Vis study of CPO-catalyzed degradation of carbamazepine
 
UV-Vis Spectra of CBZ (0.07 mM / 16.53 mg/L) and H2O2 (0.75 mM) were 
scanned in 100 mM KH2PO4 buffer, 20 mM KCl at pH 2.75 (Fig.3.1). The 
Spectrum of CBZ showed a strong absorption at 285 nm. 1 minute after addition 
of 5 nM CPO, the 285 nm absorption decreased, and stopped increasing at 4 
minutes (Fig. 3.1). Wavelength at 285 nm was used to measure kinetic 
parameter of CBZ degradation catalyzed by CPO.  
The same reaction was carried out under the same condition except for the 
chlorine ion (KCl) in phosphate buffer. Without KCl, the absorbance did not 
Figure 3.1 UV-Vis Spectra of CBZ with H2O2 and its metabolites at 1min, 2.5min and 4min. 
41 
 
change after the addition of CPO. Chlorine ion is necessary in the degradation of 
CBZ in CPO-H2O2-Cl
- system.  
According to Equation (1), The efficiency of degradation catalyze by 5 nM 
CPO was 96% within 4 minutes, the efficiency might be more than 96% since the 
the tail of the UV peak of product seemed cover the original drug (285 nm). 
3.3.2 The effect of chloride on the degradation of CBZ 
Degradation rate was calculated from 0.2-0.6 minute. The degradation rate 
increased from 0 to 18.89 µM/min. The obsevation was consistent as described 
in section 3.2.1, suggested that chloride participates in the degradation of CBZ. 
(Fig. 3.2). 
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Figure 3.2. The effect of chloride on the degradation of CBZ. Data were collected from 
triplicate experiment in 100 mM phosphate buffer at pH 3.0,  with 0.07 mM CBZ, 0.07 mM 
H2O2, and 2.5 nM CPO. 
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3.3.3 The effect of pH on the degradation of CBZ 
 
The optimum pH for the degradation of CBZ is 3.0 in the presence of 20 mM 
Cl-, the degradation efficiency decreased from pH 3.5 to 5. This curve was close 
to the expected chlorination reaction and oxidation reaction, [60] suggested CPO 
could be applied in the acid wastewater treatment. (Fig. 3.3). 
3.3.4 The effect of H2O2 concentration 
The degration rate was increased as the concentration of H2O2 increased to 
0.53 mM. From 0.53 to 0.71 mM, the rate was still stable, only decreased 
slightly.This could be due to the degradation of CPO by the high concentration of 
H2O2.[61] The stability of CPO in the presence of H2O2 compared with other 
peroxidase is suggested that CPO has a better prospect of application than the 
same class enzyme. (Fig. 3.4). 
Figure 3.3 The effect of pH on CBZ degradation.  Data were collected from triplicate 
experiment in 100 mM phosphate buffer (20 mM KCl) with 0.07 mM CBZ, 0.07 mM H2O2,  
and 2.5 nM CPO at pH 3.0. 
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3.3.5 The kinetic parameters of CBZ degradation catalyzed by CPO 
 
Different concentrations of CBZ were reacted with 0.07 mM H2O2 with 5 nM 
Figure 3.4 The effect of H2O2 concentration, Data were collected from triplicate 
experiment in 100 mM phosphate buffer (20 mM KCl) with 0.07 mM CBZ and 5 nM CPO 
at pH 3.0. 
 
Figure 3.5 The effect of CBZ concentration. Data were collected from triplicate 
experiment in 100 mM phosphate buffer (20 mM KCl) with 0.07 mM H2O2, and 5 nM 
CPO at pH 3.0, concentration of CBZ was varied from 0.02 mM to 0.11 mM. 
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CPO (Fig. 3.5). According to Equation 2, the kinetic parameters of CBZ 
degradation catalyzed by CPO was calculated (Table 3.1)  
 
Km Vmax kcat kcat/Km 
R2 
 (µM) (µM s-1)  (s
-1) (µM-1s-1) 
73.35 3.87 733 10.54 0.9995 
 
3.3.6 LC-Q-TOF- MS 
To investigate the degradation efficiency of CBZ in CPO-H2O2-Cl
- system, 
10.59 µM CBZ was reacted with 107.19 µM of H2O2 and CPO (2.9 nM) for 10 
minutes, the sample was analyzed by LC-Q-TOF-MS, CBZ was not observed, 
the degradation efficiency by low concentration of CPO could achieved 100%, 
suggesting the potential of the application of CPO in large-scale waste water 
treatment.  
Samples were detected in Agilent Technologies 6530 Accurate-Mass LC-Q-
TOF-MS in full scan MS mode, the accurate mass data of the molecular ions 
were processed through the Agilent MassHunter Qualitative Analysis software. 
There were 15 CBZ metabolites (coded from CM1 to CM15) confirmed by 
different retention times and accurate mass-to-charge ratios (m/z). The elemental 
formula, retention time, the relative mass difference between the observed mass 
and the mass of the target compound (in parts per million), and the difference 
between the observed mass and the mass of target compound (in milliDaltons) 
   Table 3.1 The kinetic parameters of CBZ degradation catalyzed CPO. 
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were collected (Table 3.2).  
 
  All the relative mass difference of the standard drug (CBZ) and metabolites 
were less than 5.0 ppm except for CM1 (6.21 ppm) and CM13 (5.14 ppm).The 
relative mass difference  of metabolite CM1 and CM13 in all experiments were 
between 0.19 ppm and 9.54 ppm, 0.74 ppm and 5.14 ppm, respectively.  The 
mass differences of all compounds were less than 2.0 mDa. This method was 
proved to be efficient for determination of the metabolites of CBZ.  
The mass spectra of each individual metabolite were collected in positive 
mode by MassHunter Workstation software (Appendix I). Since it was in positive 
Retention time Experimental mass Theoretical mass Diff Diff
 (min)  (m/z)  (m/z)  (ppm)  (mDa)
CMZ C15H12N2O 5.901 236.0943 236.0950 -2.73 -0.64
CM1 C15H12N2O2 4.314 252.0914 252.0899 6.21 1.56
CM2 C15H14N2O3 3.366 270.1004 270.1004 -0.08 -0.02
CM3 C14H11NO2 2.839 225.0790 225.0790 -0.06 -0.01
CM4 C14H9NO 6.776 207.0680 207.0684 -1.84 -0.38
CM5 C13H9N 3.970 179.0728 179.0735 -4.12 -0.74
CM6 C13H9NO 5.185 195.0678 195.0684 -3.23 -0.63
CM7 C15H13NO2 3.793 239.0938 239.0946 -3.64 -0.87
CM8 C14H9NO2 2.379 223.0630 223.0633 -1.64 -0.37
CM9 C15H11NO3 3.959 253.0748 253.0739 3.53 0.89
CM10 C16H14N2O2 4.863 266.1058 266.1055 0.88 0.23
CM11 C15H12ClNO2 6.061 273.0559 273.0557 0.90 0.25
CM12 C14H8ClN O 7.985 241.0298 241.0294 1.36 0.33
CM13 C13H8ClN 7.442 213.0356 213.0345 5.14 1.10
CM14 C13H8ClNO 6.222 229.0291 229.0294 -1.48 -0.34
CM15 C14H8ClNO2 3.111 257.0240 257.0244 -1.46 -0.38
Code Formula
Table 3.2 Accurate-Mass LC-Q-TOF-MS data for the identification of CBZ and its 
metabolites. 
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mode, all the compounds were  detected as molecular ion [M+H]+ except for 
CM9, the detected molecular ion was [M+NH4]
+ adduct (271.1085 m/z), the 
ammonium adduct formation was favored in the ion source probable due to the 
ion pairing effect on the functional group responsible of ionization. 
For chlorinated metabolites, the isotope peaks were detected as the 
conformation of addition of chlorine atom, the two major peaks of each spectra 
separated by 2 m/z units and peak heights are in the ratio of 3:1, proved these 
molecules contain one chlorine atom.  
The structures of each metabolite were confirmed in targeted MS/MS by 
retention time and fragment ions (Fig. 3.6). There were 2 types of metabolites 
based on their structure. The first type contained CM1, CM2, CM9, CM10 were 
suggestive of oxygen insertion into the CBZ-based structure. The other structures 
were the second type, structures were based on acridine (CM5), the 
decarbonylation product of parent compound. All chlorinated metabolites were 
from acridine-based structures. CM11, CM12, CM13, CM14, CM15 was the 
chlorinated product of CM7, CM4, CM5, CM6, CM8, respectively. CM7 was 
generated  from CM3 by methylation of hydroxyl group. CM8 was the 
hydroxylated product of CM4. 
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  C15H14N2O3   (CM2)                                                                   C14H11NO2  (CM3) 
 C15H12N2O   (CBZ)                                                                      C15H12N2O2  (CM1)          
  C14H9NO   (CM4)                                                                         C13H9N  (CM5) 
  C13H9NO   (CM6)                                                                         C15H13NO2  (CM7) 
Figure 3.6 The targeted MS/MS spectra of CBZ and its metabolites. 
49 
 
 
  C14H9NO2   (CM8)                                                                     C15H11NO3  (CM9)          
 C16H14N2O2   (CM10)                                                                  C15H12ClNO2  (CM11)          
 C14H8ClNO   (CM12)                                                                  C13H8ClN  (CM13)          
 C13H8ClNO   (CM14)                                                                   C14H8ClNO2   (CM15)  
 
Figure 3.6 (Cont.).The targeted MS/MS spectra of CBZ and its metabolites . 
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The concentrations of all metabolites were measured as compound area by 
MassHunter Workstation software, and presented by percentage of all 
compounds as pie chart, all chlorinated compounds were showed in the second 
pie chart at right side (Fig. 3.7)    
 
To investigate the mechanism of degradation process, the experiment was 
carried out for limited reaction time (1,3 and 5 minutes) with low concentration of 
H2O2 (6.86 µM), the ratio of the concentration of  CBZ and H2O2 was about 7:1. 
Only part of CBZ was degraded, and only several metabolites were detected 
which could be suggested as the first formed metabolites (Fig 3.8). At the first 
minute, only CM1, CM2, CM9, CM10 were formed, the four proposed structures 
were suggestive of oxygen insertion into the CBZ-based structure, produced 
directly from CBZ without decarbonylation, CM1 was the most abundant 
metabolite, suggested the first step of degradation was the epoxidation of CBZ. 
The percentage of these four compounds decreased significantly after reacted 
with higher concentration of H2O2 for longer time (Fig. 3.7). From 3 minutes, 
Figure 3.7.  The percentage of each metabolites measured by compound area.  
Metabolites shared the same structure presented by the same color.  
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acridine (CM5) was formed, CM7 and CM8, two acridine-based metabolites were 
detected at 5 minutes. The final concentrations of them were the relatively high. 
Compared with the CBZ-based structure compounds, acridine-based structure 
were suggested as the major products, acridine (CM5), the decarbonylation 
product of parent compound, with CM6, CM7 and CM8 were the major 
metabolites of the degradation catalyzed by CPO, CBZ-based structures existed 
as intermediates of the degradation. CM5, CM6, CM7 and CM8 were the most 
abundant metabolites, suggested they were the major metabolites of the 
degradation catalyzed by CPO. 
 
The chlorinated products were observed as CM11-CM15, the concentration of 
them were relatively low (Fig. 3.7) and they were not observed at the first stage 
of reaction (Fig. 3.8), these metabolites were not the major product of the 
Figure 3.8 The area of metabolites with limited H2O2 at 1 min, 3 min and 5 min detected 
by Accurate-Mass LC-Q-TOF-MS. All experiments were duplicates and data reported 
were mean values of two independent measurements. 
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degradation catalyzed by CPO.  
The chromatograms of CBZ and its metabolites were collected with their 
proposed structures (Fig. 3.9). In the chromatograms of CM1, CM2, CM9, CM11, 
CM12, CM13, CM14 and CM15, there were isomers identified by different 
retention time. For CM1, CM9, CM11 and CM12, metabolites had problem of 
signal to noise ratio might due to the low concentration, chromatograms of the 
four compounds were collected by  Agilent Technologies 6460 Triple-quadrupole 
LC/MS/MS in multiply reaction monitoring (MRM) mode. 
3.3.7 Triple-Quadruple LC/MS/MS 
Agilent Technologies 6460 Triple-Quadrupole LC/MS/MS in multiply reaction 
monitoring (MRM) mode was applied in the investigation of metabolites of CBZ, 
especially for the 3 compounds (CM1, CM9, CM11 and CM12) which the 
resolution were low in Q-TOF. Data was analyzed in Agilent MassHunter 
Qualitative Analysis software. After the formula of metabolites was confirmed by 
LC-Q-TOF-MS, different retention times of individual metabolites could be 
recognized by Triple quad with less noise than in Q-TOF. (Fig. 3.9) 
The specific parameters, including optimized fragmentor voltage and collision 
energy (CE) for different MRM transition has been determined by flow injection 
analysis without column (FIA) with MassHunter Optimizer software (Appendix II).  
 Four transitions were selected to monitor for one compound.  
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C15H12N2O   (CBZ) C15H12N2O2  (CM1)          
 
 
  C15H14N2O3   (CM2)                                                                    C14H11NO2 (CM3)
  
C14H9NO   (CM4)                                                                          C13H9N (CM5) 
  
C13H9NO   (CM6)                                                                          C15H13NO2 (CM7) 
  
 
Figure 3.9 The chromatograms of CBZ and its metabolites. 
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C14H9NO2   (CM8) C15H11NO3  (CM9) 
  
C16H14N2O2   (CM10)                                                                   C15H12ClNO2 (CM11)          
  
C14H8ClNO   (CM12)                                                                   C13H8ClN (CM13)          
  
C13H8ClNO   (CM14)                                                                    C14H8ClNO2 (CM15) 
  
Figure 3.9 (Cont.) The chromatograms of CBZ and its metabolites. 
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The information of produced ions gave a better understanding of the structure 
of metabolites than the targeted MS/MS, it provided all the fragment information 
of parent compound to help to analyze, several same transitions could suggest 
the structural similarity. For example, CM4, CM5, and CM7 shared most of their 
product ions (Table 3.3).  
 
The different elution times of the same formula was considered as isomers. 
In addition, the existence of isomers could also be suggested with distinctive 
product ions by the same fragmentor voltage at different retention time. 
3.3.8 The proposed mechanism of degradation catalyzed by CPO 
With all information above, the pathway for CBZ metabolism catalyzed by 
CPO was proposed (Fig 3.10.)  The main pathway of degradation was to form the 
10,11-expoxy carbamazepine (CM1), the C10-C11 bond was likely the most 
reactive site. The 10,11-dihydroxy carbamazepine (CM2) produced by addition of 
H2O, with both trans and cis isomers. They were major transient intermediates 
further underwent cleavage of the carbamoyl moiety and rearrangement of 
heterocycles, from azepine ring to a pyridine structure, to form 9-acridine-
The bold values were the mass of precursor ions. The italic values were estimated as the same 
fragments adducted with vary hydrogens. 
 
Table 3.3 The optimizer data of CM4, CM5 and CM7.  
Precursor ion  
Precursor ion 
(m/z)
Shared product ions
(m/z)
Independent product ions
(m/z)
C14H9NO       (CM4) 208 75, 102, 154 ,
C13H9NO       (CM5) 180 75, 102, 153 , 140
C15H13NO2     (CM7) 240  208,153, 154
180, 152 , 128,
127 , 77, 101, 51
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caboxaldehyde hydrate form (CM3). Hydroxyl group of CM3 was exchanged with 
methanol in phosphate buffer (pH 3.0), to generate methylated product CM7. 
Dehydration was the reaction happened at the same time, 9-acridine-
caboxaldehyde (CM4) was generated. CM8 was hydroxylated from CM4. Both 
CM3 and CM4 were not observed on mass spectra, because they transferred to 
their product quickly at the beginning of reaction (Fig. 3.8). Acridine (CM5) was 
formed from CM4 by cleaving aldehyde group of CM4. Further, the derivatives of 
CM5 was generated as CM6’ and CM6. CM6’ was the hydroxylated product of 
CM5, hydroxylation was at 9 position due to its low electron density. The oxidized 
metabolite, acridone (CM6) was from CM6’ by kept oxidizing at hydroxyl group 
and considered as more abundant than CM6’ according to its stable structure.  
The minor path way was from CM1’a, hydrolysis of the carbamoyl moiety, to 
form a carboxylic acid group CM9a, and further CM9a’ underwent the oxidation to 
form CM9b. CM1’a was transformed from CM2 by losing water molecule, by 
exchanged the carbamoyl moiety, CM9a was also formed. Oxcarbazepine 
(CM1’b) was oxidation of CM1’a on the hydroxyl group, and CM1’b produced 
CM9b by the same way as CM1’a to CM9a. The methylation of hydroxyl group of 
CM1a generated CM10. CM11, CM12, CM13, CM14 and CM15 were the 
chlorinated metabolites from CM7, CM4, CM5, CM6, respectively. 
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Figure 3.10 The proposed mechanism of the degradation of CBZ catalyzed by CPO. 
presented by primary structure of each metabolite. 
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3.4 Discussion 
The process of CBZ degradation catalyzed by CPO was efficient, 100 % CBZ 
was depleted at the concentration from 2.5 mg to 14.8 mg/L for minutes, or ≥96% 
with 16.5 mg/L for 4 minutes, all in nanomolar level CPO. The degradation rate 
and concentrations were conservative, removal ability are mostly likely more than 
parameters used in the experiment due to the LC samples were not monitored by 
shorter time period. 
Compared with some biological treatment in water, such as white rot fungus, 
the efficiency of CPO-catalyzed reaction was dramatically improved. For 
example, it was reported that 57% to about 70% of CBZ was removed by 
Trametes versicolor, and 46% was degraded by Ganoderma. Lucidum for 7 
days, at the original concentration of 10 mg/L (ppm). [58]   
The UV treatment, the most efficient common water treatment in degrading 
CBZ, compared with ClO2 oxidation and active sludge treatment. The UV 
radiation with 0.1 mg/L CBZ, could remove 93% of parent compound after 10 
minutes. The concentration of CBZ was 0.1 mg/L in ClO2 to remove 54% CBZ; in 
active sludge treatment with 0.2 mg/L CBZ, 16% of drug was removed. [62] For 
the other active sludge degradation experiment  with 30 µg/L CBZ, the removal of 
CBZ was not observed.[63] TiO2/UV method could reach 74% CBZ conversion 
for 2 hours with TiO2 at 100 mg/L.[59]  The complete CBZ degradation (10mg/L) 
by Fenton-like oxidation was achieved at 2 mg/L iron for 1 hour, at 50 ℃.[64]  
The new CBZ biodegradation was investigated by using freshwater microalgae 
for 10 days the percentage of degradation was 30%-37%, with initial CBZ 
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concentration at 1mg/L (ppm). With the increased of CBZ concentration, the 
degradation rate was decreased.[57] Ozonation of CBZ was likely the rapidest 
degradation treatment to CBZ in drinking water treatment system by ppm level 
ozone.[65] However, to consider about the application in large scale 
environment, CPO showed the stronger degradation ability to high concentration 
of CBZ at simple conditions (low concentration of catalyst, easy operation and 
proper reaction time), which was a potential choice industrial wastewater 
treatment.  
Most of CBZ metabolites generated by CPO-H2O2-Cl
- system were the same 
as products in the common water treatment and in environment.[58, 59, 62, 63, 
66] The CPO-H2O2-Cl
- system could be used as the environmental model to 
learn the chlorinated and oxidized reaction of specific pollutants.  
To consider the toxicity and the persistence of CBZ products, the possible 
environmental impact of metabolites should be emphasized. Although simple 
acridines were not carcinogens, acridine and its derivatives were suggestive of 
mutagenic activities.[67] Acridine and aridone showed more toxic than CMZ itself 
in different ecotoxicity assays.[53]  
There are still abundant acridine, acridone, and their derivatives after 
degradation catalyzed by CPO. The acridine and acridone are more susceptible 
to biological treatments. CPO might be applied in active sludge or with other 
microorganism to digest the major metabolites. The UV treatment showed a 
outstanding removal of acridine and acridone. CPO catalyzed degradation could 
be coupled with UV-treatment to increase the degradation efficiency. The 
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investigation of improving the depletion of toxicologically relevant metabolites of 
CBZ, such as by coupling CPO catalyzed degradation with other treatment 
should be considered in the future experiments 
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CHATPER IV. 
4.1 Background 
Over 10,000 tons level of antibiotics are estimated to be used in the U.S.A per 
year. [68] Sulfonamide pharmaceutical substances are widely used in human and 
veterinary antibacterial treatments and they are frequently detected in 
wastewater and surface water with the active sulfonamide concentration detected 
as 20 mg/L.[69] Sulfamethazine or sulfadimidine (SMZ) belongs to heterocyclic 
sulfonamides, and the concentration of SMZ has been detected to 8.7 mg/kg in 
manure.[70] Nine sulfonamide antibiotics were detected in surface water with 
SMZ as the highest one with concentration of 78.3 ng/L, SMZ resistant bacteria 
was found in the sample.[8] The detection of SMZ resistant bacteria implied the 
extensive use of SMZ increased the risk of antibacterial resistance..  
CPO showed its ability to degrade/ detoxicate drugs in our previous study, 
and  the aim of this experiment was to investigate the potential application of CPO 
in degradation of antibiotics. To evaluate CPO-H2O2-Cl
- system, the reaction 
efficiency of CPO in the degradation of SMZ would be investigated and the 
structures of metabolites and degradation pathway would be proposed. 
4.2 Experimental Procedure 
4.2.1 Material 
All material and chemicals used were the same as described in section 2.2.1. 
4.2.2 UV-Visible spectrophotometry 
A VARIAN UV-Vis spectrophotometer (Cary 200 Bio) was used to collect the 
IV. CPO-CATALYZED DEGRADTION OF SULFAMETHAZINE 
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UV spectra of the degradation products. SMZ was dissolved in methanol to make 
3.59 mM stock solution. The drug solution was scanned by dissolving 0.06 mM 
SMZ in 100 mM KH2PO4 buffer with 20 mM KCl at pH 2.75, mixed with0.06 mM 
H2O2. UV spectra were recorded after the addition of 5 nM CPO for 1minute, 2.5 
minutes and 4 minutes.  
4.2.3 Liquid chromatography and mass spectrometry  
4.2.3.1 Sample preparation 
To investigate the degradation efficiency, SMZ was dissolved in methanol to 
make a stock solution (3.59 mM), 62.45 µM (17.38 mg) of SMZ was mixed with 
1.3 nM CPO for 30 minutes at room temperature. H2O2 stock solution (41.16 mM) 
was added to reaction system at 56.5 µL/minute to make the final concentration 
of H2O2 achieved 314 µM. Mixture was centrifuged at 3,000 g in Centriprep
® 
centrifugal filter unit with a 30,000 Dalton cut-off membrane (EMD Millipore, 
Billerica, MA, USA). The filtrate was collect after centrifuged for 1 min. Ethyl 
acetate was used to extract the filtrate while shaking vigorously. The get rid of the 
organic solvent, The supernatant was evaporated to dryness. The dried residues 
were dissolved in H2O /methanol (95:5 v/v) to make the final concentration 
approximate 1 mg/L (ppm). Sample was stored at -20 ℃ in a freezer or 
immediately detected by LC-Q-TOF-MS mass spectrometer system. 
To detect all metabolites of SMZ, the same experiment above was carried out 
(3.59 mM SMZ, 314 µM H2O2 and 1.3 nM) for 1.5 hour, extracted directly by ethyl 
acetate. And nitrogen gas purge was used to get sample dried. The dried 
metabolites were dissolved in 2.0 mL H2O/methanol (95:5 v/v) to make the final 
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concentration approximate 5 mg/L (ppm). Centrifuge the sample with 1200g for 
10 minutes, 1.5 mL supernatant was removed by syringe. Filtration was applied 
by using 0.22 µM polyethersulfone syringe filter. The sample was stored at -20 ℃ 
in a freezer and detected both in LC-Q-TOF-MS. 
To investigate the mechanism of degradation in CPO-H2O2-Cl
- system, the 
sample reacted with low concentration of H2O2 was prepared. 6.86 µM H2O2 was 
added directly to Centriprep® centrifugal filter unit (30,000 Dalton cut-off) with 
35.90 µM SMZ, catalyzed by 1.3 nM CPO in the 100 mM phosphate buffer with 
20 mM KCl for 1 minute, 3 minutes and 5 minutes, filter units were centrifuged at 
3000g for 1min at room temperature, and extracted the filtrate by ethyl acetate, 
purged the organic phase with nitrogen gas to dryness. The dried metabolites 
were dissolved in H2O/methanol (95:5 v/v) to make the final concentration 
approximate 1 mg/L (ppm), and detected by LC-Q-TOF-MS system immediately. 
Experiments ran in triplicate.   
To investigate the brominated products, the reaction was also carried out in 
the buffer contained KBr instead of KCl, 62.45 µM SMZ, 2 mM H2O2, catalyzed 
by 2 nM CPO for 30 minutes. After extraction and purge procedure, the final 
concentration dissolved in the H2O/methanol (95:5 v/v) was approximate 1 mg/L 
(ppm).  
4.2.3.2 Instrumentation and chromatographic separation 
Instrumentation and chromatographic separation were the same as in section 
2.2.3.2. without the application of Triple-Quandrupole LC/MS/MS mass 
spectrometry.  
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4.2.3.3. Data Mining and Database development 
The data Mining and Database development were the same as in section 
2.2.3.3 without the application of FIA. 
4.3 Result and discussion 
4.3.1 UV-Vis study of CPO-catalyzed degradation of carbamazepine 
UV-Vis Spectra of SMZ (0.06 mM) and H2O2 (0.06 mM) were scanned in 100 
mM KH2PO4 buffer with 20 mM KCl at pH 2.75 (Fig.4.1). The Spectrum of SMZ 
showed the absorption at 241 nm, 263 nm and 306 nm. 1 minute after addition of 
5 nM CPO, the 241 nm absorption increased, and stopped increasing at 2.5 
minutes, the 263 nm peak kept decreasing. And the wavelength at 306 nm 
increased from 1minute to 2.5 minutes. The UV spectrum at 4 minutes was 
monitored, the line was the same as the wavelength at 2.5 minutes. H2O2 was 
added to the mixture solution, to make the total concentration of H2O2 increase to 
0.30 mM, after 1 minute, the 241 nm peak decreased and a strong absorption 
was observed at 273 nm (Fig. 4.1). There was no wavelength could be used to 
measure kinetic parameter of SMZ degradation catalyzed by CPO. 
The same reaction was carried out under the same condition except for the 
chlorine ion (KCl) in phosphate buffer. Without KCl, the absorbance did not 
change after the addition of CPO. Chlorine ion is imperative in the degradation of 
SMZ in CPO-H2O2-Cl
- system.  
4.3.2.1 CPO-H2O2-Cl
- system 
To investigate the degradation efficiency of SMZ in CPO-H2O2-Cl
- system, 
62.45 µM SMZ was reacted with 314 µM of H2O2 and CPO (1.3 nM) for 30 
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minutes, the sample was detected by LC-Q-TOF-MS, SMZ was not observed, the 
4.3.2 LC-Q-TOF- MS 
Degradation efficiency by nanomolar level of CPO could achieved 100%, 
suggesting the potential of the application of CPO in large-scale waste water 
treatment.  
Samples were detected in Agilent Technologies 6530 Accurate-Mass LC-Q-
TOF-MS in full scan MS mode, the accurate mass data of the molecular ions 
were processed through the Agilent MassHunter Qualitative Analysis software.  
To detected all metabolites, samples were concentrated 5 folds, there were 8 
SMZ metabolites (coded from SM1 to SM8) confirmed by different retention times 
and accurate mass-to-charge ratios (m/z). SM9 was detected only in the reaction 
with limited H2O2 within 5 minutes as an intermediate product. The elemental 
formula, retention time, the relative mass difference between the observed mass 
and the mass of the target compound (in parts per million), and the difference 
Figure 4.1 UV spectrum of SMZ degradation catalyzed by CPO 
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between the observed mass and the mass of target compound (in milliDaltons) 
were collected (Table 4.1). 
 
All the relative mass difference of the standard drug (SMZ) and metabolites 
were less than 4.0 ppm. The mass differences of all compounds were less than 
1.0 mDa. This method was proved to be efficient for determination of the 
metabolites of SMZ.  
The mass spectra of each individual metabolite were collected in positive 
mode by MassHunter Workstation software (Appendix I). Since it was in positive 
mode, all the compounds were detected as molecular ion [M+ H]+. SM7 and 
SM9 were detected as molecular ion [M+ Na] + adduct (351.0287 m/z and 
317.0677 m/z, respectively), the sodium adduct formation was favored in the ion 
source probable due to the ion pairing effect on the functional group responsible 
of ionization.  
For chlorinated metabolites with one chlorine atom in compound (SM2, SM5 
and SM7), the isotope peaks were detected as the conformation of addition of 
Table 4.1 Accurate-Mass QTOF-LC/MS data for the identification of SMZ and its metabolites 
catalyzed in CPO-H2O2-Cl- system. 
 
Code Formula
Retention time
(min)
Experimental mass
(m/z)
Theoretical mass
(m/z)
Diff 
(ppm)
Diff 
(mDa)
SMZ C12H14N4O2S 4.245 278.0832 278.0837 -1.93 -0.54
SM1 C12H14N4 3.219 214.1211 214.1218 -3.27 -0.70
SM2 C12H13ClN4 4.106 248.0829 248.0829 0.00 0.00
SM3 C12H12Cl2N4 7.295 282.0440 282.0439 0.23 0.07
SM4 C12H11Cl3N4 7.400 316.0044 316.0049 -1.71 -0.54
SM5 C12H13ClN4O2S 4.894 312.0447 312.0448 -0.13 -0.04
SM6 C12H12Cl2N4O2S 5.414 346.0054 346.0058 -1.04 -0.36
SM7 C12H13ClN4O3S 2.980 328.0398 328.0397 0.25 0.08
SM8 C12H11Cl3N4O2S 7.267 379.9668 379.9668 -0.16 -0.06
SM9 C12H14N4O3S 1.020 294.0790 294.0787 1.17 0.34
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chlorine atom, the two major peaks of each spectrum separated by 2 m/z units 
and peak heights are in the ratio of 3:1, proved these molecules contain one 
chlorine atom. For SM3 and SM6, there were 3 lines in the molecular ion region 
(M+, M+2 and M+4) with gaps of 2 m/z units between them, and with peak 
heights in the ratio of 9:6:1, it was confirmed that both compounds contain 2 
chlorines. For SM4 and SM8, compounds had the pattern 27:27:9:1.[71]  
The structures of each metabolite were confirmed in targeted MS/MS by 
retention time and fragment ions (Fig. 4.2). There were 2 types of metabolites 
based on their structures. The first type products were SO2 extrusion structures. 
(SM1, SM2, SM3 and SM4). SM1 was the product lost the sulfonyl group of SMZ, 
SM2, SM3 and SM4 were the chlorinated metabolites of SM1. The other 
structures were directly chlorination of SMZ (SM5, SM6 and SM8), and the 
hydroxylation product of SM5 was SM7. SM9 was the metabolic intermediate of 
SM7, the hydroxylated product of SMZ, it could only be detected at the beginning 
of the reaction.  
The concentrations of all metabolites were measured as compound area by 
MassHunter Workstation software, and presented by percentage of all 
compounds as pie chart, percentage less than 1% were showed in the second 
pie chart at right side (Fig. 4.3)   
To investigate the mechanism of degradation process, a experiment was 
carried out for limited reaction time (1,3 and 5 minutes) with low concentration of 
H2O2 (6.86 µM), the ratio of the concentration of  drug and H2O2 was about 5:1. 
Only part of SMZ was degraded, and 3 metabolites were detected which could 
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C12H14N4O2S (SMZ)  C12H14N4 (SM1) 
  
C12H13ClN4 (SM2)  C12H12Cl2N4 (SM3) 
 
 
C12H11Cl3N4 (SM4) C12H13ClN4O2S (SM5) 
  
C12H12Cl2N4O2S (SM6) C12H13ClN4O3S (SM7) 
  
 
Figure 4.2 The targeted MS/MS spectra of APAP and its metabolites.  
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be 
suggested as the first formed metabolites (Fig 4.4). SM1 was the most 
abundant metabolite within 5 minutes, and SM5, SM9 generated at the same 
time in lower amounts, suggested that the first step of degradation was the 
oxidation, chlorination and the loss of sulfonyl group, SM1 formed preferentially. 
The area of SM1 kept stable at first 3 minutes and showed decreased 
tendency at 5 minutes, it might due to the transformation of SM1 to chlorinated 
metabolites which under the limit of detection. The percentage of SM1 was 
26.35% in the reaction with higher concentration of H2O2 for longer reaction time, 
 
C12H11Cl3N4O2S (SM8) C12H14N4O3S (SM9) 
  
             Figure 4.2 (cont.) The targeted MS/MS spectra of APAP and its metabolites. 
Figure 4.3 The percentage of each metabolites measured by compound area. Metabolites 
shared the same structure presented by the same color (pink color represent the 
desulnonated structure, purple represent the SMZ-based group and blue presents the 
hydroxylated group). 
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whereas SM6 was the primary product finally, suggested that the desulfonylation 
reaction was predominant at the first reaction stage, and then the rate of 
chlorination significantly increased.  
SM5 had the increased tendency form 1 minute to 5 minute, the finally 
concentration of SM5 was low but its chlorinated product SM6 was the major 
metabolites, SM5 was suggested as the major intermediate metabolite. SM9 was 
not observed after reaction with high concentration H2O2 for 30 minutes, but its 
chlorinated product was detected as 0.43% of all metabolites, it was suggested 
that hydroxylated metabolites were the byproducts in the reaction. Chlorination 
and desulfonylation were the major reactions, hydroxylation was the minor 
reaction. (Fig.4.3). 
For desulfonylated metabolite SM1 and its chlorinated products SM2, SM3 
and SM4, the total concentration of them was 39.83% and the 3 chlorine atom 
addition structure (SM4) was only 0.91%. Chlorination of the desufonylated 
structure by 3 chlorine atoms was not favored in the reaction which may due to 
the structure of CPO binding pocket and the polarity in the pocket. The same 
limitation of chlorine atoms addition also applied in SMZ based structure, the total 
concentration of them was 60.17%, SM8 (0.86%) were the minor product of the 
degradation catalyzed by CPO. Two chlorine atoms were preferentially inserted 
to SMZ molecule (SM6, 58.20%) in contrast to the three chlorine atoms addition. 
(Fig 4.4)  
The chromatograms of SMZ and its metabolites were collected with their 
proposed structures (Fig. 4.5). In the chromatograms of SM2, SM3, SM4, SM5, 
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SM7, SM8 and SM9, there were isomers identified by different retention times. 
The extrusion of SO2 structure (SM1) was reported previously with structural 
rearrangement. There were two structures proposed for SM1 (Table 4.2). One is 
N1-(4,6-dimethylpyrimidin-2-yl)benzene-1 (a), 4-diamine, another is 4-(2-imino-
4,6-dimethylpyrimidin-1(2H)-yl)aniline (b). Proposed structures were presented 
by form (a) in all the spectra and chromatograms, form (a) was probably the 
actual structure of metabolite in the reaction catalyzed by CPO because of its 
less rearrangement than form 
(b). SM2-SM4 were the 
chlorinated products of SM1.In 
SM2, there were 5 isomers 
according to the 5 different 
retention times. The two major 
isomers were chlorinated on 
Structure Reference 
 
[72-75] 
 
[75-80] 
Figure 4.4 The area of metabolites with limited H2O2 at 1 minute, 3 minutes 
and 5 minutes detected by Accurate-Mass LC-Q-TOF-MS. All experiments 
were duplicates and data reported were mean values of two independent 
measurements. 
Table 4.2 Possible identities of C12H14N4 (SM1). 
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position 1 and 2 because of the high electron density of aniline group and the 
metabolite chlorinated at position 1 (Fig. 4.5) was assumed as the most 
abundant product because of its electron density, –NH2 group  on benzene ring 
was an electron donating group (EDG) , whereas sulfonyl group was electron 
withdrawing group. Other isomers were also suggested first be chlorinated or 
hydroxylated on the aniline group at the carbon atoms which located close to 
amine. 
SM5 had 5 different chlorinated sites which corresponded to 5 different 
retention time, major metabolites were chlorinated at position 1,2 and 3, the 3rd 
position was on the dimethylpyrimidine group (Fig 4.5). The other two were 
proposed to assign to the two amine groups.  SM6 only showed one retention 
time, there was one structure was stable, other structures may exist but with the 
amount under the limit of detection. The chlorine atoms probably added to the 
aniline group near primary amine due to the high electron density and it was a 
typical chlorination catalyzed by CPO.[39]  SM8 was the byproduct with one 
more chlorine atom addition based on SM7, the two retention times suggested 2 
isomer structures, one additional chloride sites were on the aniline group near -
NH2 or on the dimethylpyrimidine. 
SM7 and SM9 were the hydroxylated products of SMZ, although in TiO2/UV 
method, the pyrimidinyl moiety of SMZ was suggested to be hydroxylated, in 
CPO reaction, phenyl portion were proposed to be hydroxylated according to the 
MSMS spectrum. [81] The hydroxylation of aromatic amine in SMZ was also 
reported in the biodegradation catalyzed by white rot fungus.[72] However, 
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C12H14N4O2S (SMZ)  C12H14N4 (SM1)  
  
C12H13ClN4 (SM2)  C12H12Cl2N4 (SM3)  
  
C12H11Cl3N4 (SM4)  C12H13ClN4O2S (SM5)  
  
C12H12Cl2N4O2S (SM6)  C12H13ClN4O3S (SM7)    
 
 
 
           Figure 4.5. The chromatograms of CBZ and its metabolites. 
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according to CPO chlorination preference, the hydroxylation was recommended 
mainly at phenyl portion. 
The mechanism of degradation catalyzed by CPO was proposed considering 
all information above, the pathway for SMZ metabolism catalyzed by CPO was 
proposed, each metabolite showed by one of its proposed chemical structures 
instead of all isomers. For CPO-H2O2-Cl
- system (Fig 4.6), the chlorinated steps 
with one and two chlorine atoms addition and desulfonylation of SMZ were the 
major pathways. The minor path way was hydroxylation and chlorination with 
three chlorine atoms. 
4.3.2.2 CPO-H2O2-Br
- system 
To investigate the halogenation of SMZ catalyzed by CPO, 20 mM KBr was 
applied in the buffer instead of KCl, the CPO-H2O2-Br
- system reaction was 
carried out at the room temperature, and the product spectrum was obtained 
(Appendix I) There were only 3 metabolites detected. All of them were 
brominated products. (Table 4.3) [71] There were two peaks (357.0027 m/z and  
 
C12H11Cl3N4O2S (SM8)   C12H14N4O3S (SM9)   
  
          Figure 4.5. (cont.) The chromatograms of CBZ and its metabolites. 
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Figure 4.6. The proposed mechanism of the degradation of SMZ catalyzed by CPO-H2O2-Cl- 
system presented by primary structure of each metabolite. 
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Figure 4.7 The percentage of 
the three metabolites  
measured by compound area 
(catalyzed by CPO-H2O2-Br- 
system). 
SM6-Br
51.10%
SM8-Br
48.83%
SM5-Br
0.07%
 
368.9995 m/z) in approximately 1:1 ratio in the mass spectrum of SM5-Br, 
confirming compound contained 1 bromine atom. For SM6-Br, there were three 
peaks (434.9117 m/z, 436.9090 m/z and 438.9074) in 1:2:1 ratio, suggested 2 
bromines addition to the parent compound. The ratios of 3 bromine atoms 
contained molecule are 1:3:3:1, which was observed in the mass spectrum of 
SM8-Br, suggested the number of bromine in this metabolite. 
In the CPO-H2O2-Br
- system, neither the loss of sulfonyl group, nor the 
hydroxylation was observed (Fig 4.7). Compared 
with the chlorination of SMZ, bromination was 
favorable to form the product with 3 halogen atoms 
addition (48.83%). 
Halogenation, hydroxylation and desulfonylation 
were suggested as competitive reactions in the 
SMZ degradation catalyzed by CPO. When buffer 
contained bromide, with competitive pathway was 
predominantly changed to halogenation. This 
result was consistent with our previous result that the rate of halogenation in the 
presence of bromide was higher than chloride.[28]  
 
Code Formula
Retention time
(min)
Experimental mass
(m/z)
Theoretical mass
(m/z)
Diff 
(ppm)
Diff 
(mDa)
SM5-Br C12H13BrN4O2S 5.390 355.9948 355.9943 1.65 0.59
SM6-Br C12H12Br2N4O2S 6.095 433.9042 433.9048 -1.28 -0.55
SM8-Br C12H11Br3N4O2S 8.258 511.8144 511.8153 -1.66 -0.85
Table 4.3 Accurate-Mass LC-Q-TOF-MS data for the identification of SMZ and its metabolites 
catalyzed in CPO-H2O2-Br
- 
system. 
 
77 
 
 
Figure 4.8 The mass spectra and chromatograms of SMZ brominated metabolites. 
 
The structures were confirmed by targeted MSMS, and the chromatograms of  
 
each metabolite were collected. (Fig 4.8).  
There was only one peak in each chromatogram, demonstrated that there 
was no isomer of brominated product. Bromination showed higher halogenated 
selectivity in the SMZ, it was presumably due to the formation of Br2 during the 
CPO catalyzation. The halogenation might occur in the solution or the wide 
C12H13BrN4O2S (SM5-Br) MSMS spectra C12H13BrN4O2S (SM5-Br) chromatogram 
  
C12H12Br2N4O2S (SM6-Br) MSMS spectra C12H12Br2N4O2S  (SM6-Br) chromatogram 
  
C12H11Br3N4O2S (SM8-Br) MSMS spectra C12H11Br3N4O2S  (SM8-Br) chromatogram 
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channel of CPO, reacted with the free bromine. This assumption also consistent 
with the only one retention time of SM6, Cl2 
might release and reacted with SMZ 
directly by two chlorinated sites. It was 
suggested that HClO formed in the 
catalyzation to chlorinate substrate, 
however in chlorination of SMZ by 
hypochlorite, the product was only reported 
as SM5, HClO would not be the only 
crucial intermediate involved in the 
chlorination.[82] 
For CPO-H2O2-Br
- system, there was 
only one pathway to elucidate the 
mechanism of SMZ halogenation. (Figure 
4.9) 
4.4 Discussion 
The process of SMZ degradation 
catalyzed by CPO was efficient, 100 % 
SMZ was depleted at the concentration 
from 17.38 mg/L for minutes by the 
nanomolar level CPO. The degradation rate and substrate concentrations were 
conservative, removal ability are mostly likely more than parameters used in the 
experiment due to the LC samples were not monitored by shorter time period. 
Figure 4.9.The mechanism of SMZ 
bromination catalyzed by CPO 
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The major metabolite in environment was N4-acetyl-sulfamethazine.The 
desulfonylated products generated by CPO-H2O2-Cl
- system are more 
susceptible to future biological degradation.[70] 
Compared with some biodegradation treatment in water, such as white rot 
fungus, the efficiency of CPO-catalyzed reaction was dramatically improved. For 
example, it was reported 9 mg/L SMZ was removed by Trametes versicolor for 
20 hours.[72] The 62%±4% SMZ was removed within 8 minutes when 36 µM 
SMZ reacted with 360 µM MnO2.[8] 
It was reported that in different types of treatments (photolysis, UV/H2O2, 
UV/persulfate and persulfate oxidation) with 20 µM SMZ for 45 minutes, the 
removal rate of SMZ achieved 15.1% to 96.5%. The UV/H2O2 achieved 87.5%, 
the most effective method was UV/persulfate, however this reaction required 200 
µM sulfate to accomplish 96.5% degradation, 500 µM sulfate to accomplish 
100% degradation. As it stated by the author, the persulfate addition may cause 
environmental problem.[79] 
 The degradation of SMZ was not significantly observed after 8 hours when 
treated by sodium hypochlorite, and used more than one month to degrade 
substrate.[83] 
CPO catalyzed degradation has the potential to apply in large scale wastewater 
treatment considering about the nanomolar level enzyme and the rapid sample 
preparation. 
The oxidation and chlorination products of SMZ generated in CPO-H2O2-Cl
- 
system could be found in most of the water chlorination treatment and 
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biodegradation process.[72, 75, 83] CPO-H2O2-Cl
- system might be used as the 
environmental model to learn the chlorinated and oxidized reaction of specific 
pollutants.  
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CHAPTER V. 
5.1 Introduction 
Glutamic acid 183 (Glu 183) of CPO located closely to the heme iron in the 
distal pocket, suggested its function to in the cleavage of the peroxide O-O bond. 
[20] It is an important acid-base catalyst in the formation of compound I. In a 
mutagenensis study, Glu 183 was replaced by histidine residue, the mutant’s 
chlorination and dismutation activity were decreased to 15% and 50%, 
respectively.[23] The result implied that the Glu 183 affects predominately 
V. ENGINEERING THE HYDROGEN BOND OF CPO BY MUTANT H105R  
Figure 5.1 The Proposed mechanism of His 105 in the cleavage of the peroxide O-O bond.  
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chlorination activity, but not essential for it. The hydrogen bond linked to 183 and 
the distal pocket structure might affect the enzyme activity, mutant E183H could 
still form hydrogen bond with histidine 105(His 105) to facilitate the cleavage of 
peroxide O-O bond. 
His 105 was located in the heme distal pocket, formed hydrogen bond with 
glutamic acid 183. His 105 is 3.5 Å form the propionate carboxyl group, it might 
be critical in peroxide O-O cleavage by forming a hydrogen bond with Glu183 
which position the carboxyl group toward the heme iron. The hydrogen bond 
between H105 and E183 was suggested to play an essential role in modulating 
the chlorination activity. (Fig. 5.1) [1, 21] When H105 was replaced by a small 
and nonpolar amino acid alanine (H105A) to decrease the polarity and destroyed 
chlorination decreased. [85]  
To investigate the function of the hydrogen bond between histidine and 
glutamic acid, mutant H105R was created by changing histidine 105 to arginine 
to increase the hydrogen bonding strength.  
5.2 Experimental Procedure 
5.2.1 Materials 
A filamentous fungus Aspergillus niger (A. niger, MGG029) were purchased from 
American Type Culture Collection (Manassas, VA). Gene expression vector 
pCPO3.I-Amds which is coding for WT CPO and co-transformation plasmid 
pAB4.1 with PyrG selection marker (GenBank accession no. AJ300448) were 
obtained TNO Microbiology and Systems Biology, Netherlands. Ultra-Pfu DNA 
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polymerase and The QuikChange II XL sitedirected mutagenesis kit   were 
purchased from Stratagene (La Jolla, CA). Lysing enzyme (L1412) was from 
Sigma- Aldrich (St. Louis, MO) Purified oligonucleotide primers were obtained 
from Eurofins MWG Operon (Huntsville, AL). All other chemicals were purchased 
from Thermo Fisher scientific (Waltham, MA).  De-ionized water was produced 
by using a Milli-Q®  Biocel™ Ultra-Pure water purifier system equipped with 0.22 
µM membrane filter cartridge (EMD Millipore, Billerica, MA, USA), purification 
cartridge and an organic removal cartridge (Evoqua Water Technologies, Lowell, 
MA, USA). 
5.2.2 Construction of H105R mutant and plasmid propagation 
To investigate the function of His 105 and the relation between His 105 and 
Glu183, the H105R mutation was created by site -directed mutagenesis. Vector 
pCPO3.I-Amds, a 14 kb plasmid was used as template. A.nidulans acetamidase 
gene (AmdS) was inserted into NotI restriction enzeme digestion site as a 
selection marker, to allow the mutant contains Amds to grow on acetamide plate, 
consuming acetamide as the sole source of nitrogen. The full encoded CPO 
gene, pCPO3.I is placed under control of the A. niger glucoamylase promoter 
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(PglaA) and A. nidulans anthranilate synthetase terminator (TtrpC). (Fig. 5.2) 
 
        Encoded primers for H105R mutant was 5’-gag ccc cac gct ttc gag cgc gac 
c-3’(primer 1) and 5’-gcg gga gaa gga gtg gtc gcg ctc g-3’(primer 2), both with the 
melting temperature of 74.42℃.The PCR was carried out by QuikChange II XL 
sitedirected mutagenesis kit and Eppendorf thermal cycler (Mastercycler 
gradient) , PfuUltra HF DNA polymerase was added to reaction.The PCR 
reaction was set up at 98 ℃ for 50 seconds, followed by 18 cycles of  98℃ for 30 
Figure 5.2 The CPO expression vector pCPO3.1-AmdS for transformation  of A.niger strain.[2] 
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seconds for denaturation, 63 ℃ for 30 seconds for annealing, 72 ℃ for 14 
minutes for extension, the last cycle was hold at 72 ℃ for 10 minutes.  
DPN I restriction endonuclease was applied to digest the templates. PCR 
product was propagated in E. coli strain (H105R). Plasmids from E. coli was 
extracted by QIAGEN DNA extraction mini kit (QIAGEN, CA). The extracted DNA 
was examined by DNA electrophoresis and confirmed by DNA sequencing (Fig. 
5.3) 
5.2.3 Transformation into A. niger and selection for expression 
The A. niger MGG029 strain was inoculated in 50 mL minimal medium (MM) 
containing maltose (5%), glucose (1%), casamino acids (0.5%), yeast extract 
(0.5%), NaNO3 (70mM), KCl (7 mM), K2HPO4 (6 mM), MgSO4 (2 mM), uridine (10 
mM), carbenicillin (50 mg/L), the Hutner trace elements solution (50 µL).[84] The 
culture was incubated for 37 ℃ at 250 rpm for 1 day and change to 30 ℃ for 2-5 
days, homogenizer was used to disrupted mycelia for 20 seconds, repeated 3 
times. Then the culture was transferred to 1 L media with the same compositions 
as in 50 mL MM, incubated at 30 ℃ for 20 hours at 250 rpm.  
Mycelia was resuspended in 1.7 Osm solution (0.27 M CaCl2 and 0.6 M NaCl) 
after fi ltered through sterile myracloth. Protoplasts were incubated with lysing 
enzyme (L1412) at 37 ℃ for 4 hours at 150 rpm, resuspended protolasts and 
incubated on ice for 20 minutes, then centrifuged at 3500 rpm for 15-30 minutes 
at 0 ℃ to get precipitate. The supernatant was decanted, precipitate was  
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washed twice by STC 1700 buffer (1.2 M sorbitol, 10 mM Tris-HCl, 50 mM CaCl2 
and 35 mM NaCl at pH 7.5), resuspended by STC 1700 and incubated with10 µg 
mutant plasmid and 1 µg pAB4.1 co-transformation plasmid at 25 ℃ for 25 
minutes. The incubated protoplast was mixed with 60% PEG 4000 in 10 mM Tris-
HCl buffer at pH 7.5 and 50 mM CaCl2 carefully in three steps. The PEG-treated 
protoplast was diluted to 10 mL with STC 1700 and collected through 
centrifugation. The protoplast was resuspended in the leftover of STC1700 and 
spread onto 1.2 M sorbitol selective agar medium plate, incubate for 3 -5 days at 
22 ℃. 
5.2.4 Expression of the H105R mutant protein 
Mutant colonies on the selective plates were inoculated in MM (without 
uridine and yeast extract, addition of 0.1 mM 5-Aminolevulinic acid hydrochloride 
(heme precursor) for 22 ℃ at 250 rpm for 7 days.  
MCD assay and ABTS assay of the culturing medium were used to 
determine the protein yield by its chlorination and peroxidation activity, 
respectively. 
MCD assay was measured at 278 nm by UV-Vis spectroscopy. 0.17 mM 
monochlorodimedone (MCD) was mixed with 50-500 uL culture medium in 100 
mM KH2PO4 buffer with 20 mM KCl at pH 2.75, after addition of 2 mM H2O2, 
absorbance at 278 nm was monitored for 1 minute.  
1.7 mM 2, 2’-azino-bis-3-ethy-benzthiazoline-6-sulfonic acid (ABTS) was 
mixed with 50 µL clear culture medium in 100 mM KH2PO4 buffer with 25 mM 
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citric acid at pH 3.0, after addition of 2 mM H2O2, the UV started to collect the 
absorbance at 405 nm for 1 minutes. 
Due to decreased tendency of ABTS activity after 2-3 days since inoculation, 
and totally destroyed activity after Amicon stirring pressure cell, 0.05 mM 
ferriprotoporphyrin IX chloride (hemin) was added to culture to stabilized the 
mutant.  
5.2.5 Purification of the mutant protein 
After 7 days, the 12 Liter medium was filtered through myracloth and glass 
fiber filter circles G6 to remove fungus, concentrated to 50 mL in the Amicon 
ultrafiltration cell. 50 mL crude sample was dialyzed in 4 liters 25 mM phosphate 
buffer at pH 5.9 for 12 hours, and repeat dialysis again with fresh buffer. The 
sample was filtered by 0.45 µM membrane. 
Ion exchange chromatography was applied by diethylaminoethyl (DEAE) 
sepharose fast flow column with 50 mL DEAE resin. 25 mM phosphate buffer at 
pH 5.9 with ionic strength gradient was used to wash the colunm, gradually 
increase the concentration of NaCl from 0.0 to 0.5 M. Different eluted portions 
were collected and concentrated by Centriprep® centrifugal filter unit (30,000 
Dalton). Absorption spectrum was scanned and SDS-PAGE was used to check 
the existence of mutant. 
All buffers used in column were filtered through 0.45 µM membrane and 
degassed for 15 minutes to remove solid and gas particles. Purification by 
columns was carried out in 4 ℃ to keep protein stable. 
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Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was 
used to check the molecular size of eluted products. 
5.3 Result and discussion 
5.3.1 Mutant DNA sequencing       
 
                       
In the sequencing result, the Histidine codon CAC was replaced by Arginine 
codon CGC successfully. The GC content was as high as 72%, but PCR protocol 
still work effectively. 
5.3.2 Transformaiton and expression result 
H105R mutant grown on 1.2 M sorbitol selective agar plate after 
transformation suggested the transformation was successful. The colonies were 
inoculated to 12 L medium and monitored 
the expression of protein by MCD and 
ABTS assays. There was no MCD activity 
showed in mutant medium, only ABTS 
assay could be used to evaluate the 
expression. The ABTS activity was high 
at the second day of inoculation, and 
Figure 5.3 DNA sequence of H105R mutant. 
Figure 5.4 H105R mutant grown on 1.2 
sorbitol selective agar plate after 24 hours. 
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quickly decreased. (Fig. 5.5).  
50 µM hemin was added to culture to stabilized the protein, repeated the 
same protocol to 12 liters culture. 
 
5.3.3 Purification   
The purification of concentrated sample was collected to run SDS-PAGE with 
samples from the crude medium and other portion of elution product. (Fig. 5.6) 
The band of mutant was presented in SDS-PAGE, the concentrated sample 
(lane2) was of transparent color, implying the heme was not incorporated into 
protein. 
In UV-Vis spectrum of concentrated sample (lane 2), the low-spin ferric heme 
protein typically with a Soret band around 420 nm was not observed (Fig. 5.7), 
indicating the heme incorporation was not e fficient in H105R mutant, the 
recombinant H105R mutant was apoprotein.   
Figure 5.5 The ABTS activity of H105R cultures since the second day of inoculation. 
Samples were run in triplicate. 
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5.4 Discussion 
The apoprotein H105R was suggested that arginine might change the distal 
pocket due to its charge or structure, and even result in the instability of heme 
Figure 5.6 SDS-PAGE of mutated protein. Lane 1-the crude sample before ion exchange; 
lane 2-ion exchange eluted products (band of H105R in red rectangle); lane 3-products 
eluted by buffer with 1M NaCl.  
Figure 5.7 UV-Vis spectra of H105R mutant. 
91 
 
porphyrin. Although H105 could be changed to alanine (A), the structure of CPO 
would not change much due to the smaller size of alanine.  
The chlorination activity was not found during all the process, suggested that 
the chlorination active site in CPO was not formed. The change of distal pocket 
affected the chlorination dramatically and the role of H105 site was crucial in 
supporting the CPO construction near the heme center. 
The peroxidation decreased during culturing and amicon concentration, 
implied that mutated protein was easy to be denatured. The H105 has the ability 
to stabilize E183 by hydrogen bond, changing it to a larger and more polar amino 
acid might destroy the structure and function of CPO by affected E183. 
There is also possibility that the change from histidine to arginine might 
directly change the tertiary structure of mutant protein. In conclusion, the amino 
acid at 105 site could be changed to arginine but could not express active protein 
due to heme incorporation failure. 
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Abstract 
Non-steroidal anti-inflammatory drugs (NSAIDs), such as diclofenac and naproxen, 
are widely used for the treatment of arthritis, ankylosing spondylitis, and acute muscle 
pain. However, most NSAIDs are usually not metabolized and simply pass through 
human body. These drugs are difficult to be decomposed by general waste treatment 
strategies and have caused serious environmental concerns. Here we report a rapid and 
efficient enzymatic degradation of diclofenac and naproxen by chloroperoxidase (CPO), 
a heme protein isolated from Caldarimyces fumago (C. fumago). Complete dagradation 
of diclofenac and naproxen was achieved in only 9 and 7 min for diclofenac and 
naproxen, respectively, under mild conditions with nanomolar enzyme concentration. 
The degraded products were identified by both HPLC-MS and NMR, suggesting the 
involvement of multiple steps in CPO catalyzed degradation of the two drug molecules. 
Moreover, our work demonstrated that CPO treatment followed by existing 
bioremediation technologies (activated sludge) greatly improved the efficiency and 
completeness of decontaminating these two drugs from waste water. Most significantly, 
our eco-toxicity test using green algae, Chlorella Pyrenoidos, showed that the products 
had noticeably lower toxicity than the parent drugs, demonstrating the potential of CPO 
in large-scale treatment of sewage contaminated with diclofenac and naproxen. 
Keywords: enzymatic degradation; diclofenac; naproxen; chloroperoxidase; eco-toxicity 
1. Introduction 
Both diclofenac (2-[(2,6-dichlorophenyl)amino]benzeneacetic acid; sodium salt) and 
naproxen (2-(6-methoxynaphthalen-2-yl)propionic acid) (Fig. 1) are non-steroidal anti-
inflammatory drugs (NSAIDs). They are widely used in the treatment of arthritis, 
ankylosing spondylitis, acute muscle pain, and other symptoms associated with 
inflammation (Grenni et al., 2013; Sathishkumar et al., 2012). The widespread 
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application of these drugs coupled with their resistance toward metabolic breakdown in 
human body inevitably resulted in the release of large amount of these drugs into the 
aquatic environment. In recent years, diclofenac and naproxen has been detected in 
surface water, groundwater, wastewater, and even in drinking water at concentrations 
ranging from ng·L-1 to μg·L-1 (Zhang et al., 2008; Zhao et al., 2009). It has been reported 
that naproxen has adverse effects on biota, such as impairing the lipid peroxidation 
system of bivalves and altering microbial community structure to yield antibiotic 
resistance in environmental microbial communities (Gagné et al., 2006). Diclofenac was 
recently designated as a devastating environmental pollutant because of its 
bioaccumulation in the food chain (Ilic et al., 2011). Therefore, effective degradation of 
these drugs is of paramount significance for reducing their accumulation in the 
environment. 
Unfortunately, conventional sewage treatment is inefficient in removing or degrading 
diclofenac and naproxen (Hartmann et al., 2008; Nakada et al., 2006). For example, no 
noticeable breakdown of diclofenac was observed over a period of 28 days either when 
it was the sole source of carbon or when an external carbon source was added for co-
metabolic degradation (Quintana et al., 2005). Batch tests using an activated sludge 
system and membrane bioreactors also revealed very poor degradability of diclofenac in 
comparison with other pharmaceuticals (Samaras et al., 2013). Other conventional water 
treatment processes such as coagulation, sedimentation and filtration have all been 
proven to be ineffective to remove these two drugs (Brillas et al., 2010; Westerhoff et al., 
2005). Consequently, physicochemical approaches including ultrasonic (Naddeo et al., 
2010), electrochemical oxidation (Faber et al., 2012), photocatalytic (Arriaga et al., 
2008), potassium permanganate oxidation (Álvarez et al., 2013) and ozone oxidation 
(Naddeo et al., 2009) have been adopted to improve the removal of these drugs from 
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drinking water or wastewater. However, limitations of these methods, such as cost, 
efficiency, and secondary pollution from use of chemicals, warrant further investigations 
on the removal/breakdown of these widely used drugs from environment. 
Little evidence of diclofenac transformation by microbial communities is documented 
in the literature. White-rot fungi (WRF) were found to be efficient in degrading both 
diclofenac (Urrea et al., 2010) and naproxen (Urrea et al., 2010), but long treatment time 
(1 h and 5 h, respectively) was needed. Enzymatic degradation is an ideal approach 
because of the mild and environmentally friendly conditions employed. Thus, crude lignin 
peroxidase (LiP, a heme-imidazole peroxidase) from Phanerochaete chrysosporium (P. 
chrysosporium) has been used to convert diclofenac in various conditions and was found 
to be highly effective (Zhang et al., 2010). In addition, fungal unspecific peroxygenases 
(UPOs) have been shown to be able to hydroxylate/O-demethylate a diverse array of 
pharmaceuticals (including diclofenac and naproxen)(Hofrichter et al., 2014; Kinne et al., 
2009; Piontek et al., 2013; Poraj-Kobielska et al., 2011; Wang et al., 2013). Inspired by 
the results of LiP and UPOs, we studied the degradation of diclofenac and naproxen by 
chloroperoxidase (CPO), a heme containing glycoprotein that is phylogenetically (heme-
thiolate proteins) and functionally (haloperoxidases) related to UPOs with higher 
oxidation potential and thermal/chemical stability than LiP (Makino et al., 1976; Millis et 
al., 1989). High performance liquid chromatography-mass spectrometry (HPLC-MS) and 
nuclear magnetic resonance (NMR) spectroscopy were employed to identify the major 
degradation products. Based on the products identified, reaction pathways are 
postulated. Our results demonstrated that CPO can effectively convert both diclofenac 
and naproxen into compounds that are significantly less toxic based on their inhibitory 
effects and EC50 value on the growth of a freshwater green alga, Chlorella pyrenoidos.
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2. Experimental 
2.1 Enzyme preparation  
 Chloroperoxidase was isolated from the growth medium of C. fumago according to the 
method of Morris and Hager (Morris et al., 1966) with minor modifications, using acetone 
rather than ethanol in the solvent fractionation step. CPO with Rz =1.03 (A398/A280, 1.44 
for pure enzyme) was prepared and stored in 100 mM phosphate buffer (pH 5.0) at 4 °C. 
The halogenation activity of CPO used in this study was 4232 U·mL-1 based on the 
standard monochlorodimedon (MCD) assay (Hager et al., 1966). The aromatic 
hydroxylation activity (3563 U·mL-1) of the enzyme was determined by monitoring the 
hydroxylation of naphthalene into 1-naphthol (Kluge et al., 2007). The classic peroxidase 
activity of the enzyme determined using ABTS (2,2'-azino-bis(3-ethylbenzothiazoline-6-
sulphonic acid)) as substrate was 3071 U·mL-1 (Manoj et al., 2008). 
2.2 Reagents and buffers  
 All reagents used in this study, including diclofenac, naproxen, dipotassium hydrogen 
phosphate, potassium dihydrogen phosphate, hydrogen peroxide (30 % in aqueous 
solution), ethyl acetate, and inorganic reagents for cultivating the green alga were 
obtained from Xi′an Chemical Co. Ltd (Xi’an, China) with highest purity (≥ 98%). Other 
chemicals such as methanol and acetonitrile (chromatography grade) as well as 
standard degradation product of the two drugs, o-desmethylnaproxen and 4’-
hydroxydiclofenac (chromatography grade) were purchased from Sigma Aldrich (St. 
Louis, MO USA). 
Phosphate buffer (0.1 mol·L-1) was prepared by mixing appropriate volumes of 1 
mol·L-1KH2PO4 and K2HPO4 stock solutions and diluting the combined solutions to 1 L. 
Then the solution was adjusted to various pH with 1 mol·L-1 H3PO4. All solutions were 
prepared using deionized water with a conductivity of 5.6×10-8 s·cm-1. 
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2.3 Degradation of diclofenac and naproxen  
 Enzymatic degradation of both drugs was carried out in 0.1 mol·L-1 phosphate buffer in 
a centrifugal tube with a total volume of 3.0 mL containing CPO (0.25-23 nmol·L-1), 20 
mmol·L-1 KCl, and drugs (15 µmol·L-1) at pH 2~6 at 298K. The reaction was started by 
adding H2O2 (0.015-0.3 mmol·L
-1) in the absence of light under magnetic stirring and was 
continued for 20 min. The supernatant of the reaction mixture was extracted 3 times 
using ethyl acetate. The combined organic extract was concentrated by rotary 
evaporation (0.09 MPa, 308K) to remove the solvent. The extracts were then dissolved 
in acetonitrile and methanol, respectively, for HPLC (LC-20AT, Shimadzu) analysis. The 
mobile phase consisted of 80:20 (v/v) acetonitrile and water for diclofenac and 90:10 
(v/v) methanol and water for naproxen, and the flow rate was 0.5 ml·min-1. The detector 
was set at 274 nm and 235 nm for diclofenac and naproxen, respectively. The 
quantitative analysis of the target compounds was based on the standard curve 
(correlation coefficients were > 0.999). 
Degradation efficiency     %100/ 00  CCC t       (1) 
The effect of reaction parameters (pH, concentration of enzyme/H2O2, and reaction 
time) on degradation efficiency was investigated and optimized.  
All experiments were triplicated and data reported were mean values of three 
independent measurements. 
2.4 Determination of products  
 Samples were treated as above for HPLC-MS analysis. An Esquire LC-ion trap mass 
spectrometer (Bruker Daltonics, Germany) equipped with an orthogonal geometry 
Electrospray Ionization (ESI) source was employed to determine the formulae of the 
products. Nitrogen was used as the drying (8 L·min-1) and nebulizing (0.8 bar) gas at 
180 °C. Scanning was performed from m/z 100 to 1000 in the standard resolution mode. 
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To establish the structure of the degradation products, the reaction was carried out 
using the same condition as stated above except a larger volume (300 mL) was used. 
Upon completion of the reaction, the reaction mixture was extracted with either ethyl 
acetate or chloroform. After removal of the solvent by rotary evaporation (0.09 MPa, 
308K) the extracts were dissolved in either deuterated chloroform or methanol and 
transferred to 5 mm NMR tubes. NMR experiments were carried out on a Bruker 600 
MHz NMR spectrometer operating at a proton frequency of 599.73 MHz. All spectra 
were recorded at 298 K using standard pulse programs from the manufacturer. 
2.5 Elimination of COD and TOC  
 Total organic carbon (TOC) measurement was conducted on a TOC-VCPA analyzer 
(Shimadzu Corp.). The feed speed was 150 ml·min
-1
. Chemical oxygen demand (COD) 
was measured by a quick method on a Rapid Autoanalyzer (5B-1(F), Lian-hua Tech.Co., 
Ltd). A solution containing 2.5 ml sample, 0.7 ml reagent D (potassium dichromate) and 
4.8 ml reagent E (catalysts) in a 20.0 ml glass tube was heated to 438K and kept for 10 
min together with a blank sample and a standard sample. After 2 min of air cooling, the 
heated solution was cooled by water for another 2 min. Then the absorbency of the 
samples was measured at 610 nm. 
2.6 Treatment of drug effluent by activated sludge  
 A mixed population of activated sludge microorganisms was collected from Xi'an second 
sewage treatment plant (Xi’an, China). The sample of activated sludge was filtered on a 
Spectra Mesh polypropylene 149-μm filter (Spectrum Laboratories Inc., Rancho 
Dominguez, CA, USA) to remove aggregates. The sample was then washed three times 
by centrifugation and suspended in the same volume of culture medium. To remove any 
excessive amounts of dissolved organic carbon, the suspension was stirred and 
maintained under oxygen at 298K for at least 24 h without exposure to the test materials. 
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The volatile ratio f of activated sludge was 0.74.  
90 mL of 15 µmol·L-1 drug effluent was put into the activated sludge suspension 
before /after enzymatic treatment (to ensure a final drug concentration of 7.5µmol·L-1). 
The samples were stirred for the duration of the study with a magnetically coupled stirrer 
when air was used as the aerated gas. The sample was then left to stand for 1-2 h. The 
supernatant was taken for determination of COD. 
2.7 Toxicity Tests  
 Freshwater unicellular green alga, C. pyrenoidosa (provided by the Institute of Wuhan 
Hydrobiology, Chinese Academic of Science), was cultivated in nutrient media of blue 
green medium (BG11) at 298K and illuminated with cool-white fluorescent lights at a 
continuous light intensity of 2000 Lx. For cell experiments, C. Pyrenoidosa was exposed, 
during its log growth phase, to the toxicant at five different concentrations (maintain final 
concentration ranging from 0.01 to 0.36 mg/L) for 3-4 days at 298K. The concentration of 
the alga was determined by monitoring the change of absorption at 680 nm (Ma et al., 
2006). The toxicity tests for each drug concentration were conducted in triplicate. 
The growth inhibition rate i for each sample was calculated from Equation (2) and (3) 
(Lange et al., 2006), 
   0/lnln 0 ttODOD tt    (2) 
      (3) 
where t-t0 is incubation time (min); ODt0 is absorbance at t0; ODt is absorbance at t; μ is 
growth rate of all life (min-1); μc is growth rates of control culture without toxin addition 
(min-1); and μt is growth rates of cultures in the presence of drugs (min
-1). EC50 (drug 
concentration required to cause 50% reduction in growth) values were calculated using 
linear regression analysis of drug concentration as natural logarithm versus percentage 
 c / 100%t ci     
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inhibition. All correlation coefficients were > 0.99. 
3. Results and discussion 
3.1 Effect of reaction parameters on drug Degradation  
 Since various physicochemical parameters influence the degradation efficiency, it is 
essential to optimize these factors in order to make the process more efficient and 
practically applicable. 
The pH range investigated was 2-6 due to poor stability and activity of CPO at higher 
pH. Fig. S1 (A) showed that the degradation efficiency of naproxen and diclofenac 
increased rapidly with increasing pH, and reached maximum around pH 3.2. The 
degradation efficiency decreased sharply when pH was increased above 3.2. The 
preference for such a low reaction pH has been observed for most CPO catalyzed 
reactions and has been attributed to the protein’s unique active site structure and 
catalytic mechanism (Liu et al., 2014; Zhang et al., 2012). CPO uses a glutamic acid 
(Glu 183) as the acid-base catalyst to aid the formation of compound I (Sundaramoorthy 
et al., 1995; Wang et al., 2003). The protonation of Glu183 is necessary for both the 
formation of compound I and the binding of negatively charged substrates to avoid 
unfavorable electrostatic interactions. Acidic environment is also needed to protonate 
compound X involved in most CPO catalyzed halide dependent reactions (Chiang et al., 
1976; Dawson et al., 1988). 
  It is well known that high concentration of H2O2 (oxidant) inactivates most heme 
containing enzymes due to internal oxidative destruction of the porphyrin prosthetic 
group (Grey et al., 2007). Thus low concentrations of H2O2 are employed for reactions 
catalyzed by most heme peroxidases. This strategy cannot be simply applied to CPO 
because of its ability to disproportionate hydrogen peroxide. Therefore, the optimum 
concentration of hydrogen peroxide needs to be determined based on the actual 
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substrate. The effect of H2O2 concentration on CPO catalyzed degradation of diclofenac 
and naproxen is shown in Fig. S1B. As expected for all peroxidases, no degradation of 
either drug was observed before the addition of H2O2. The degradation efficiency of both 
drugs increased as H2O2 concentration is increased. Maximum rate is achieved when 
total H2O2 concentration reached 0.1 mmol·L
-1. Further addition of H2O2, however, 
repressed the degradation of both drugs possibly due to formation of compound III 
caused by high concentrations of H2O2 (Ayala et al., 2011). Therefore, 0.1 mmol·L
-1 of 
H2O2 was chosen in the degradation of both diclofenac and naproxen in all subsequent 
experiments. 
  Optimizing CPO concentration not only improves degradation efficiency but also saves 
cost of operation. The range of CPO concentration tested was 0.25-6.0 nmol·L
-1 
for 
diclofenac and 1-23.0 nmol·L-1 for naproxen. Fig. S1 (C) showed that degradation 
efficiency of both drugs increased rapidly as CPO concentration was increased. 
Complete degradation of the drugs was achieved when CPO concentration was above 
5.0 nmol·L-1 for diclofenac, and 20.0 nmol·L-1 for naproxen, indicating that CPO is 
extremely efficient in the degradation of the subject drugs. 
  It is remarkable to note that CPO degrades both diclofenac and naproxen with a 
remarkable rate. As shown in Fig. S1 (D), about 70% of diclofenac and 75% of naproxen 
is degraded within 1 min. The complete degradation was achieved in only 9 and 7 min 
for diclofenac and naproxen, respectively, at optimum reaction condition.  
3.2 Determination of products by HPLC-MS and NMR  
 Tremendous efforts have been made to characterize the intermediates and final 
products generated from diclofenac and naproxen degradation (Faber et al., 2012; Urrea 
et al., 2010). Plausible mechanisms have been proposed for both drugs based on the 
intermediates and final products identified from different processes. To understand the 
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mechanisms of CPO catalyzed degradation and to evaluate the potential of this 
enzymatic method in environmental and industrial applications, both HPLC-MS and 
NMR analyses are employed to establish the structures of the putative products from the 
two drugs.  
  The hydroxylation of aromatic rings and O-demethylation of esters have been reported 
for several unspecific peroxygenase (UPOs) (Hofrichter et al., 2014; Kinne et al., 2009; 
Piontek et al., 2013; Poraj-Kobielska et al., 2011; Wang et al., 2013), a class of heme-
thiolate proteins related to CPO and cytochromes P450. However, these two activities 
have not been reported for CPO. In this work, CPO catalyzed hydroxylation of dic lofenac 
and O-demethylation of naproxen were observed. The degradation of both diclofenac 
and naproxen was confirmed by HPLC analysis of the reaction product as shown in Fig. 
2. The MS spectra of samples from diclofenac degradation (Fig.2) suggested the 
formation of six putative products. The peak that eluted at 2.6 min (Fig.2A) shows a 
molecular ion [M-H]- at m/z 311, indicating the addition of an oxygen atom to the parent 
compound. Multiple possibilities exist as oxygen can be added at all possible positions of 
the two benzene rings. However, NMR analysis (Fig.3) suggested compound [II] as the 
major product corresponding to this molecular ion. Since the coupling pattern of the 
chloride bearing ring remained in the product, the oxygen must have been added to the 
acetate bearing ring with oxygen added at the para-carbon of the imino group. The NOE 
between peak “a” at 3.77 ppm (singlet, 2H) and peak “b” at 7.25 ppm (Fig.S3), the 
COSY correlation and splitting pattern confirm the structure of compound [II] as reported 
previously (Blum et al., 1996; Calza et al., 2006; Coelho et al., 2009; Osorio et al., 2014; 
Sparidans et al., 2008). Product [I], 4’-hydroxydiclofenac, is commercially available and 
displays a quite different NMR spectral pattern as shown in Fig. S4 and Fig. S5). The 
peak eluted at 3.1 min (Fig.2B) displayed a molecular ion [M-H]- at m/z 328, indicating 
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the addition of two oxygen atoms to the parent compound or the addition of one oxygen 
atom to compound [II]. This product also showed a major fragmentation ion at m/z 284 
(Fig.2B), assignable to the decarboxylation of the major product. Decarboxylation was 
also observed for diclofenac itself (Fig.S6). The NMR spectrum (Fig.S7) of this product 
showed the absence of a three proton coupling pattern in the aromatic region as 
displayed by both the parent compound and compound [II], suggesting the oxygen atom 
is added to the chloride bearing ring as shown in compound IV. This is in good 
agreement with observations made with other methods (Blum et al., 1996; Calza et al., 
2006; Osorio et al., 2014). The peak eluted at 2.7 min showed a molecular ion [M-H]- at 
m/z 325 (Fig.2C), assignable to compound [V] or [VI] due to further oxidation of product 
[II] or [IV]. However, neither compound V nor VI was detected in NMR experiments, 
implicating that these products might form only in the ionization process within mass 
spectrometer. 
Based on the products identified from our LC-MS and NMR analysis, the sequence of 
diclofenac degradation catalyzed by CPO is proposed (Fig.4). The diverse catalytic 
activity of CPO makes it possible to produce a broad array of products from diclofenac 
degradation, however, under the conditions employed in our study, only hydroxylation 
activity is observed. This can be appreciated by the similarity between CPO and 
cytochromes P450 that metabolize most xenobiotics via hydroxylation. Thus CPO 
converts diclofenac to either monohydroxylated or dihydroxylated products, the same as 
the major products observed in the metabolism of diclofenac (Blum et al., 1996; Osorio 
et al., 2014). The close similarity among possible hydroxylation products makes it difficult 
to isolate and purify individual product. This drawback does not comprise the aim of this 
study. 
The identification of products from CPO catalyzed degradation of naproxen is 
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achieved by detailed NMR analysis of the products with the aid of MS. The most 
noticeable difference between proton NMR spectra of the products and the parent drug, 
naproxen, is the absence of the methoxy signal (peak “i” around 3.9 ppm, Fig.S8 and 
S9) in the products as shown in Fig.5. This suggests the demethylation of naproxen as 
reported previously (Sidelmann et al., 2001; Urrea et al., 2010). Although CPO catalyzed 
N-demethylation has been reported (Kedderis et al., 1980), the observed O-
demethylation represents a novel activity of CPO. This is reminiscent of the activity 
displayed by P450 (Meunier et al., 2004) and UPOs (Hofrichter et al., 2014; Kinne et al., 
2009) that are structurally related to CPO. The methyl (peak “a” at 1.53 ppm, doublet, 
J=6.56, 3H) and the methine (peak “b” at 4.99 ppm, quartets, J=6.56, 1H) signals from 
the product are indicative of the propionic acid part of naproxen. These signals are 
downfield shifted compared to the corresponding signals in the parent drug molecule, 
consistent with observations reported previously(Sidelmann et al., 2001; Urrea et al., 
2010). Both the methyl and the methine signals displayed NOE to a peak at 7.42 ppm 
(peak “h”, doublet, J=1.18, 1H) and a peak at 7.48 ppm (signal “c”, doublet of doublet, 
J=8.03 and 1.18, 1H) as shown in Fig.5 (A). The peak at 7.48 ppm is strongly coupled to 
a peak at 8.09 ppm (resonance “d”, doublet, J=8.03, 1H) as shown in Fig.5 (B). The 
NOE and coupling pattern of this product suggests no modification occurred to the 
propionic group bearing ring of naproxen during degradation. The remaining aromatic 
signals, peak “g” at 7.44 ppm (doublet, J=10.11, 1H) and peak “f” at 6.44 ppm (doublet, 
J=10.18, 1H) are strongly coupled (Fig.5 (B)), demonstrating their vicinal relationship. 
Based on the above NMR spectral property, this product is proposed to be 2-(5,6-
dihydroxynaphthalen-2-yl)propanoic acid due to modification at 5-C of naproxen. 
However, the NMR spectra of commercially available desmethylnaproxen (Fig. S10 and 
Fig. S11) do not support the proposed structure of this degradation product. 
106 
 
Furthermore, the MS of this product shows a molecular ion [M-H]- at m/z 311, also 
inconsistent with the structure proposed (expected m/z at 231). The difference of a mass 
of 80 between the expected and the observed mass, suggests the phosphorylation of 
one of the hydroxyl groups. Esterification of desmethylnaproxen has been reported 
previously (Sidelmann et al., 2001). The high phosphate concentration and the 
extremely low pH used in our degradation study make it feasible to phosphorylate 2-(5,6-
dihydroxynaphthalen-2-yl)propanoic acid and give product (I) as shown in Figure 6. 
Product (I) can be further degraded to 2-(5,8-dihydroxy-6-(phosphonooxy)naphthalen-2-
yl)propanoic acid via hydroxylation at the 8-C. However, this product is not observed in 
either NMR or MS experiments. The observation of a molecular ion [M-H]- at m/z 325 
suggests the formation of product (II) as shown in Fig.6. 
Based on the major products identified from our study, the reaction sequence of 
naproxen degradation catalyzed by CPO is proposed (Fig.7). Similar as the degradation 
of diclofenac, CPO catalyzed degradation of naproxen is achieved primarily via CPO’s 
monooxygenase activity. Thus CPO degrades naproxen to either monohydroxylated or 
dihydroxylated products, similar as the major products observed in bacterial degradation 
of naproxen (Wojcieszyńska et al., 2014). Initially, naproxen was degraded to 
desmethylnaproxen (Aresta et al., 2006; Urrea et al., 2010). The desmethylnaproxen is 
then phosphorylated to [(2-(6-(phosphonooxy)naphthalen-2-yl)acetic acid [a], not 
observed)] in the presence of high concentrations of phosphate and under low pH 
condition employed. Esterification of desmethylnaproxen has been reported in the 
literature (Sidelmann et al., 2001). Next, [a] was hydroxylated to 2-(5-hydroxy-6-
(phosphonooxy)naphthalen-2-yl)propanoic acid [I] corresponding to m/z 311 observed in 
Figure 6. Product (I) was then degraded to 2-(5,8-dihydroxy-6-
(phosphonooxy)naphthalen-2-yl)propanoic acid [b, expected m/z=327] which is instantly 
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oxidized to 2-(5,8-dioxo-6-(phosphonooxy)-5,8-dihydronaphthalen-2-yl)propanoic acid 
(II, m/z=325) as shown in Fig.6.  
The products identified in our NMR and MS analysis are subjected to further oxidative 
transformation as supported by the results from activated sludge experiment as well as 
eco-toxicity test.  
3.3 Reduction in chemical oxygen demand (COD) and total organic carbon (TOC) 
  Table 1 showed that only 4.9% , 9.1% of COD and 25%, 7.6% of TOC removal was 
achieved for diclofenac and naproxen, respectively. It is therefore proposed that CPO 
catalyzed degradation can serve as an efficient pre-treatment step in waste water 
treatment. This can be combined with subsequent bioremediation technologies 
(activated sludge) for complete decontamination of the two drugs in waste water. 
3.4 Combined treatment of drug effluent by enzymatic oxidation and activated sludge  
  As indicated in Table 1, the COD value of drug effluent did not decrease noticeably 
after CPO-treatment. However, compared with the parent drugs, the products from CPO 
catalyzed degradation have improved solubility in aqueous media and are more 
vulnerable to further biodegradation. This conclusion was confirmed by the observation 
that treatment of CPO-catalyzed reaction mixture with activated sludge increased COD 
removal from 4.9% and 9.1% to 85% and 86% for diclofenac and naproxen, respectively. 
On the other hand, treatment by activated sludge alone only removes 49% and 54%, of 
the COD for diclofenac and naproxen, respectively, suggesting that more effective 
decontamination of the two drugs can be achieved through CPO pre-treatment followed 
by existing bioremediation technologies (activated sludge).  
3.5 Evaluation of the eco-toxicity of the products  
  In some cases simple destruction of a drug is inadequate, since the resulting products 
may also be highly toxic, and special attention must therefore be paid to toxicity 
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assessment of products to ensure that the agent has been effectively detoxified. 
However, toxicity evaluation about the products from diclofenac and naproxen are not 
readily available. Biological assays offer a direct measure to evaluate the magnitude of 
the potential health risk of chemicals. Therefore, a growth-inhibitory test was carried out 
using C. Pyrenoidosa. 
Fig.S10 showed that the 72-h EC50 increased with the increase in degradation 
efficiency. The value was 0.25 mg·L-1 for diclofenac and 0.33 mg·L-1 for naproxen at the 
end of degradation. These results demonstrated that the products had lower toxicity 
compared with the parent drugs, suggesting the great potential of using CPO as an 
efficient catalyst in the safe removal of these drugs from environmental. 
4. Conclusion 
In summary, our study demonstrated that CPO catalyzed oxidative degradation is a 
promising alternative for treatment of waste water containing non-steroidal anti-
inflammatory drugs. Complete degradation of diclofenac and naproxen is reached in only 
9 and 7 min, respectively, under mild conditions.  
The products identified by HPLC-MS suggested the initial hydroxylation of the drug 
molecules followed by further oxidative transformation. The biodegradability of the 
decomposition products was significantly increased as confirmed by COD measurement 
after combining the enzymatic oxidation with activated sludge treatment. Most 
significantly, the products of both diclofenac and naproxen had dramatically lower 
toxicity than the original drugs as judged by the 72-h EC50 value of C. Pyrenoidos. Our 
results demonstrates that CPO can serve as an efficient, cost-effective, and 
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environmentally friendly catalyst for large-scale treatment of waste water contaminated 
with the two drugs studied in this work.. 
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Figure captions: 
Fig. 1 Chemical structures of diclofenac (a) and naproxen (b) 
Fig. 2 ESI-ion trap mass spectra of the degradation products from CPO catalyzed 
oxidation of diclofenac recorded in negative mode. 
Fig. 3 COSY of diclofenac product [II] in chloroform-d. 
Fig. 4 Proposed degradation pathway of diclofenac during CPO-catalytic oxidative  
process. 
Fig. 5 Proton NMR (A) NOESY and (B) COSY spectra of naproxen product [I]. The week 
NOEs between peaks “a” and “c” and between peaks “b” and “c” can only be 
observed at lower contour levels. The NOE and coupling patterns unequivocally 
define the structure of this degradation product. 
Fig. 6 ESI-ion trap mass spectra of the degradation products from CPO catalyzed 
oxidation of naproxen recorded in negative mode. 
Fig. 7 Proposed degradation pathway of naproxen during CPO-catalytic oxidative 
process. 
 
Table 1 Elimination of COD and TOC by CPO catalyzed oxidative degradation.  
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Fig. 1 Chemical structures of diclofenac (a) and naproxen (b) 
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Fig. 2  ESI-ion trap mass spectra of the degradation products from CPO catalyzed 
oxidation of diclofenac recorded in negative mode.  
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Fig. 3 COSY of diclofenac product [II] in chloroform-d. 
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Fig. 4 Proposed degradation pathway of diclofenac during CPO-catalytic oxidative 
process. 
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Fig. 5 Proton NMR (A) NOESY and (B) COSY spectra of naproxen product [I]. The week 
NOEs between peaks “a” and “c” and between peaks “b” and “c” can only be 
observed at lower contour levels. The NOE and coupling patterns unequivocally 
define the structure of this degradation product. 
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Fig. 6 ESI-ion trap mass spectra of the degradation products from CPO catalyzed 
oxidation of naproxen recorded in negative mode.  
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Fig. 7 Proposed degradation pathway of naproxen during CPO-catalytic oxidative 
process  
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Table 1 Elimination of COD and TOC by CPO catalyzed oxidative degradation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
substance 
COD 
(mg ·L-1) 
COD removal 
(%) 
TOC 
(mg ·L-1) 
TOC removal 
(%) 
diclofenac 41→39 4.9 8.3→6.2 25 
naproxen 22→20 9.1 158→146 7.6 
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Supporting Information 
 
Fig. S1 The relationship between degradation efficiency and reaction condition of CPO 
catalyzed degradation of diclofenac (left) and naproxen (right). 
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Fig. S2 The HPLC elution profile of degradation solution both of diclofenac and naproxen  
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Fig. S3 NOESY of diclofenac product [II] 
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Fig. S4. COSY of authentic 4’-hydroxydiclofenac purchased from Sigma Aldrich 
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Fig. S5. NOESY of authentic 4’-hydroxydiclofenac purchased from Sigma Aldrich 
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Fig. S6. MS of diclofenac 
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Fig. S7. COSY of diclofenac product [IV] 
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Fig. S8. COSY of naproxen 
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Fig. S9. NOESY of naproxen 
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Fig. S10. COSY of authentic desmethylnaproxen purchased from Sigma Aldrich 
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Fig. S11. NOESY of authentic desmethylnaproxen purchased from Sigma Aldrich 
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Fig. S12. Dependence of EC50 value on degradation efficiency of diclofenac (A) and 
naproxen (B). (Green algae (ODt0=0.05) and final substrate concentration 
range 0.15-0.36 mg·L-1) 
 
 
137 
 
 
 
1. W.H.O, Pharmaceuticals in drinking-water, W.L.C.-i.-P. Data, Editor. 2012. 
2. Conesa, A., et al., Expression of the Caldariomyces fumago 
chloroperoxidase in Aspergillus niger and characterization of the 
recombinant enzyme. Journal of Biological Chemistry, 2001. 276(21): p. 
17635-17640. 
3. Holm, J.V., et al., Occurrence and distribution of pharmaceutical organic 
compounds in the groundwater downgradient of a landfill (Grindsted, 
Denmark). Environmental Science & Technology, 1995. 29(5): p. 1415. 
4. Ternes, T.A., Occurrence of drugs in German sewage treatment plants 
and rivers. Water research (Oxford), 1998. 32(11): p. 3245-3260. 
5. Triebskorna, R., et al., Toxic effects of the non-steroidal anti-inflammatory 
drug diclofenac. Aquatic Toxicology, 2004. 68(2): p. 151-166. 
6. Parrott, J.L. and B.R. Blunt, Life-cycle exposure of fathead minnows 
(Pimephales promelas) to an ethinylestradiol concentration below 1 ng/L 
reduces egg fertilization success and demasculinizes males. 
Environmental Toxicology, 2004. 20(2): p. 131-141. 
7. Fent, K., A.A. Weston, and D. Caminada, Ecotoxicology of human 
pharmaceuticals. Aquatic Toxicology, 2005. 76(2): p. 122-159. 
8. Ou, D., et al., Contamination of sulfonamide antibiotics and 
sulfamethazine-resistant bacteria in the downstream and estuarine areas 
of Jiulong River in Southeast China. Environmental Science and Pollution 
Research International, 2015. 22(16): p. 12104-12113. 
9. Baquero, F., J.L. Martinez, and R. Canton, Antibiotics and antibiotic 
resistance in water environments. Current Opinion in Biotechnology, 2008. 
19(3): p. 260-265. 
REFERENCE 
138 
 
10. Jones, O.A., et al., Pharmaceuticals: a threat to drinking water? Trends in 
Biotechnology, 2005. 23(4): p. 163-167. 
11. Benotti, M.J., et al., Pharmaceuticals and endocrine disrupting compounds 
in U.S. drinking water. Environmental Science & Technology, 2009. 43(3): 
p. 597-603. 
12. Reddersena, K., T. Heberera, and U. Dünnbierb, Identification and 
significance of phenazone drugs and their metabolites in ground- and 
drinking water. Chemosphere, 2002. 49(6): p. 539-544. 
13. Vestel, J., et al., Use of acute and chronic ecotoxicity data in 
environmental risk assessment of pharmaceuticals Ecotoxicity data and 
environmental risk assessment. Environmental Toxicology and Chemistry, 
2016. 35(5): p. 1201-1212. 
14. Ziylan, A. and N.H. Ince, The occurrence and fate of anti-inflammatory and 
analgesic pharmaceuticals in sewage and fresh water: Treatability by 
conventional and non-conventional processes. Journal of Hazardous 
Materials, 2011. 187(1-3): p. 24-36. 
15. Ternes, T.A., Occurrence of drugs in German sewage treatment plants 
and rivers. Water Research, 1998. 32(11): p. 3245-3260. 
16. Kasprzyk-Hordern, B., The removal of pharmaceuticals, personal care 
products, endocrine disruptors and illicit drugs during wastewater 
treatment and its impact on the quality of receiving waters. Water 
Research 2008. 43(2): p. 363-380. 
17. Lin, A.Y.-C., J.H.-F. Hsueh, and P.K.A. Hong, Removal of antineoplastic 
drugs cyclophosphamide, ifosfamide, and 5-fluorouracil and a vasodilator 
drug pentoxifylline from wastewaters by ozonation. Environmental Science 
and Pollution Research International, 2015. 22(1): p. 508-515. 
18. Morris, D.R. and L.P. Hager, Chloroperixdase  I.Isolation and properties of 
the crystalline gylcoprotein. The Journal of Biological Chemistry, 1966. 
241(8). 
139 
 
19. Conesa, A., et al., C-terminal propeptide of the Caldariomyces fumago 
chloroperoxidase: an intramolecular chaperone? FEBS Lett., 2001. 
503(2,3): p. 117-120. 
20. Sundaramoorthy, M., J. Terner, and T.L. Poulos, The crystal structure of 
chloroperoxidase: a heme peroxidase–cytochrome P450 functional hybrid. 
Structure, 1995. 3(12): p. 1367-1378. 
21. Wang, X., et al., Two-dimensional NMR study of the heme active site 
structure of chloroperoxidase. The Journal of Biological Chemistry, 2003. 
278(10): p. 7765-74. 
22. Kuhnel, K., et al., Crystal structures of chloroperoxidase with its bound 
substrates and complexed with formate, acetate, and nitrate. The Journal 
of Biological Chemistry, 2006. 281(33): p. 23990-8. 
23. Yi, X., et al., Examining the Role of Glutamic Acid 183 in 
Chloroperoxidase Catalysis. Journal of Biological Chemistry, 2003. 
278(16): p. 13855-13859. 
24. Manoj, K.M. and L.P. Hager, Chloroperoxidase, a Janus Enzyme. 
Biochemistry, 2008. 47(9): p. 2997-3003. 
25. Hager, L.P., et al., Chloroperoxidase. IX. The structure of compound I. 
Journal of the American Chemical Society, 1972. 94(12): p. 4364-4366. 
26. Palcic, M.M., et al., Spectrum of Chloroperoxidase Compound I. 
Biochemical and biophysical research communications, 1980. 94(4): p. 
1123-1127. 
27. Nakajima, R., I. Yamazaki, and B.W. Griffin, Spectra of chloroperoxidase 
Compounds II and III. Biochemical and Biophysical Research 
Communications, 1985. 128(1): p. 1-6. 
28. Zhang, R., et al., Spectroscopic and QM/MM investigations of 
Chloroperoxidase catalyzed degradation of orange G. Archives of 
Biochemistry and Biophysics, 2016. 596: p. 1-9. 
140 
 
29. Colonnaa, S., et al., Recent biotechnological developments in the use of 
peroxidases. Trends in Biotechnology 1999. 17(4): p. 163-168. 
30. Hofrichter, M. and R. Ullrich, Heme-thiolate haloperoxidases: versatile 
biocatalysts with biotechnological and environmental significance. Applied 
Microbiology and Biotechnology, 2006. 71(3): p. 276-288. 
31. Manoj, K.M., Chlorinations catalyzed by chloroperoxidase occur via 
diffusible intermediate(s) and the reaction components play multiple roles 
in the overall process. Biochimica et Biophysica Acta, 2006. 1764(8): p. 
1325-1339. 
32. Libby, R.D., et al., Defining the involvement of HOCl or Cl2 as enzyme-
generated intermediates in chloroperoxidase-catalyzed reactions. Journal 
of Biological Chemistry, 1992. 267(3): p. 1769-75. 
33. Osborne, R.L., et al., Caldariomyces fumago chloroperoxidase catalyzes 
the oxidative dehalogentation of chlorophenols by a mechanism involving 
two one-electron steps. Journal of the American Chemical Society, 2007. 
129(48): p. 14838-14839. 
34. Murphy, C.D., Fluorophenol oxidation by a fungal chloroperoxidase. 
Biotechnology letters, 2007. 29(1): p. 45-49. 
35. Potter, D.W., D.W. Miller, and J.A. Hinson, Identification of acetaminophen 
polymerization products catalyzed by horseradish peroxidase. The Journal 
of Biological Chemistry, 1985. 260(22): p. 12174-80. 
36. Gallati, H., Horseradish peroxidase: a study of the kinetics and the 
determination of optimal reaction conditions, using hydrogen peroxide and 
2,2'-azinobis 3-ethylbenzthiazoline-6-sulfonic acid (ABTS) as substrates 
(author's transl). Journal of Clinical Chemistry and Clinical Biochemistry, 
1979. 17(1): p. 1-7. 
37. Hager, L.P., et al., Chloroperoxidase. II. Utilization of halogen anions. The 
Journal of Biological Chemistry, 1965. 241(8): p. 1769-1777. 
141 
 
38. Libby, R.D., et al., Chloroperoxidase halogenation reactions. Chemical 
versus enzymic halogenating intermediates. The Journal of Biological 
Chemistry, 1982. 257(9): p. 5030. 
39. Vázquez-Duhalta, R., et al., Biocatalytic chlorination of aromatic 
hydrocarbons by chloroperoxidase of Caldariomyces fumago. 
Phytochemistry, 2001. 58(6): p. 929-933. 
40. Zaks, A. and D.R. Dodds, Chloroperoxidase-catalyzed asymmetric 
oxidations: substrate specificity and mechanistic study. Journal of the 
American Chemical Society, 1995. 117(42): p. 10419. 
41. Kiljunen, E. and L.T. Kanerva, Novel applications of chloroperoxidase: 
enantioselective oxidation of racemic epoxyalcohols. Tetrahedron: 
Asymmetry, 1999. 10(18): p. 3529-3535. 
42. Zhang, J., et al., Efficient decolorization/degradation of aqueous azo dyes 
using buffered H2O2 oxidation catalyzed by a dosage below ppm level of 
chloroperoxidase. Chemical Engineering Journal, 2012. 191: p. 236. 
43. Zhang, X., et al., Combination of enzymatic degradation by 
chloroperoxidase with activated sludge treatment to remove 
sulfamethoxazole: performance, and eco-toxicity assessment. Journal of 
Chemical Technology & Biotechnology, 2016: p. n/a-n/a. 
44. Wu, S., L. Zhang, and J. Chen, Paracetamol in the environment and its 
degradation by microorganisms. Applied microbiology and biotechnology, 
2012. 96(4): p. 875-884. 
45. Larsen, F.S. and J. Wendon, Understanding paracetamol-induced liver 
failure. Intensive care medicine, 2014. 40(6): p. 888-890. 
46. Frama, M.S. and K. Belitzb, Occurrence and concentrations of 
pharmaceutical compounds in groundwater used for public drinking-water 
supply in California. The Science of the total environment, 2011. 409(18): 
p. 3409-3417. 
142 
 
47. Al Qarni, H., et al., Investigating the removal of some pharmaceutical 
compounds in hospital wastewater treatment plants operating in Saudi 
Arabia. Environmental science and pollution research international, 2016: 
p. 1-12. 
48. Karaman, R., et al., Paracetamol biodegradation by activated sludge and 
photocatalysis and its removal by a micelle–clay complex, activated 
charcoal, and reverse osmosis membranes. Environmental technology, 
2016: p. 1-14. 
49. Bessems, J.G., et al., 3,5-Disubstituted analogues of paracetamol. 
Synthesis, analgesic activity and cytotoxicity. Chemico-Biological 
Interactions, 1995. 98(3): p. 237-50. 
50. Xianwen Yi, M.M., Kelath M. Manoj, Xiaotang Wang, and Lowell P. Hager, 
Replacement of the proximal heme thiolate ligand in chloroperoxidase with 
a histidine residue. Proceedings of the National Academy of Sciences - 
PNAS, 1999. 96(22). 
51. Chiron, S., E. Gomez, and H. Fenet‡, Nitration processes of 
acetaminophen in nitrifying activated sludge. Environmental Science & 
Technology, 2010. 44(1): p. 284. 
52. Tudur Smith, C., Carbamazepine versus phenytoin monotherapy for 
epilepsy. Cochrane database of systematic reviews, 2002(2): p. 
CD001911. 
53. Donner, E., et al., Ecotoxicity of carbamazepine and its UV photolysis 
transformation products. The Science of the total environment, 2013. 443: 
p. 870-876. 
54. Parolini, M., et al., Cytotoxicity assessment of four pharmaceutical 
compounds on the zebra mussel (Dreissena polymorpha) haemocytes, gill 
and digestive gland primary cell cultures. Chemosphere (Oxford), 2011. 
84(1): p. 91-100. 
55. Andrade-Mena, C.E. and C.E. Andrade‐mena, Effects of Carbamazepine 
on Murine Humoral and Cellular Immune Responses. Epilepsia 
(Copenhagen). 35(1): p. 205-208. 
143 
 
56. Singh, G., P.H.i. Driever, and J.W. Sander1, Cancer risk in people with 
epilepsy: the role of antiepileptic drugs. Brain (London, England : 1878), 
2005. 128(1): p. 7-17. 
57. Xiong, J.-Q., Biodegradation of carbamazepine using freshwater 
microalgae Chlamydomonas mexicana and Scenedesmus obliquus and 
the determination of its metabolic fate. Bioresource technology, 2016. 205: 
p. 183-190. 
58. Ernest Marco-Urreaa, et al., Ability of white-rot fungi to remove selected 
pharmaceuticals and identification of degradation products of ibuprofen by 
Trametes versicolor. Chemosphere (Oxford), 2008. 74(6): p. 765-772. 
59. Achilleos, A., et al., UV-A and solar photodegradation of ibuprofen and 
carbamazepine catalyzed by TiO2. Separation science and technology, 
2010. 45(11): p. 1564-1570. 
60. Thomas, J.A., D.R. Morris, and L.P. Hager, Chloroperoxidase. VII. 
Classical peroxidatic, catalatic, and halogenating forms of the enzyme. J 
Biol Chem, 1970. 245(12): p. 3129-34. 
61. Manoj, K.M., et al., Explaining the atypical reaction profiles of heme 
enzymes with a novel mechanistic hypothesis and kinetic treatment. PloS 
one, 2010. 5(5): p. e10601. 
62. Kosjek, T., et al., Fate of carbamazepine during water treatment. 
Environmental science & technology, 2009. 43(16): p. 6256-6261. 
63. Kruglova, a., et al., Biodegradation of ibuprofen, diclofenac and 
carbamazepine in nitrifying activated sludge under 12°C temperature 
conditions. The Science of the total environment, 2014. 499: p. 394-401. 
64. Monsalvo, V.M., et al., Application of Fenton-like oxidation as pre-
treatment for carbamazepine biodegradation. Chemical engineering 
journal (Lausanne, Switzerland : 1996), 2014. 264: p. 856-862. 
144 
 
65. Mcdoqell, D., et al., Ozonation of Carbamazepine in Drinking Water: 
Identification and Kinetic Study of Major Oxidation Products. 
Environmental science & technology, 2005. 39(20): p. 8014-8022. 
66. Golan-Rozen, et al., Transformation Pathways of the Recalcitrant 
Pharmaceutical Compound Carbamazepine by the White-Rot Fungus : 
Effects of Growth Conditions. Environmental science & technology, 2015. 
49(20): p. 12351-12362. 
67. Ferguson, L.R. and W.A. Denny, The genetic toxicology of acridines. 
Mutation research, 1991. 258(2): p. 123-160. 
68. Alastuey, A., D. Barceló, and SpringerLink, Emerging organic 
contaminants and human health. Handbook of environmental chemistry ; v. 
20. 2012, Heidelberg ; New York: Springer. 
69. Verlicchia, P., et al., Hospital effluents as a source of emerging pollutants: 
An overview of micropollutants and sustainable treatment options. Journal 
of hydrology (Amsterdam), 2010. 389(3-4): p. 416-428. 
70. Haller, M.Y., et al., Quantification of veterinary antibiotics (sulfonamides 
and trimethoprim) in animal manure by liquid chromatography–mass 
spectrometry. Journal of chromatography. A, 2002. 952(1-2): p. 111-120. 
71. Lee, T.A., A beginner's guide to mass spectral interpretation. 1998, 
Chichester ; New York: Wiley. 
72. García-Galán, M.J., et al., Biodegradation of sulfamethazine by Trametes 
versicolor: Removal from sewage sludge and identification of intermediate 
products by UPLC–QqTOF-MS. The Science of the total environment, 
2010. 409(24): p. 5505-5512. 
73. Neafsey, K., X. Zeng, and A.T. Lemley, Degradation of sulfonamides 
inaqueous solution by membrane anodic fenton treatment. Journal of 
agricultural and food chemistry, 2010. 58(2): p. 1068-1076. 
74. Saidi, I., et al., Flow electrolysis on high surface electrode for 
biodegradability enhancement of sulfamethazine solutions. Journal of 
145 
 
electroanalytical chemistry (Lausanne, Switzerland), 2013. 707: p. 122-
128. 
75. Carstens, K.L., et al., Sorption and photodegradation processes govern 
distribution and fate of sulfamethazine in freshwater–sediment 
microcosms. Environmental science & technology, 2013. 47(19): p. 
10877-10883. 
76. Unold, M., et al., Transport and transformation of sulfadiazine in soil 
columns packed with a silty loam and a loamy sand. Journal of 
contaminant hydrology, 2009. 103(1-2): p. 38-47. 
77. Schwarz, J., M.-O. Austc, and S. Thiele-Bruhnc, Metabolites from fungal 
laccase-catalysed transformation of sulfonamides. Chemosphere (Oxford), 
2010. 81(11): p. 1469-1476. 
78. Gao, J., et al., Transformation of sulfamethazine by manganese oxide in 
aqueous solution. Environmental science & technology, 2012. 46(5): p. 
2642-2651. 
79. Gaoa, Y.-q., et al., Ultraviolet (UV) light-activated persulfate oxidation of 
sulfamethazine in water. Chemical engineering journal (Lausanne, 
Switzerland : 1996), 2012. 195-196: p. 248-253. 
80. Fana, Y., et al., Kinetic and mechanistic investigations of the degradation 
of sulfamethazine in heat-activated persulfate oxidation process. Journal 
of hazardous materials, 2015. 300: p. 39-47. 
81. Fukahori, S. and T. Fujiwara, Photocatalytic decomposition behavior and 
reaction pathway of sulfamethazine antibiotic using TiO2. Journal of 
environmental management, 2015. 157: p. 103-110. 
82. Ramakrishnan, K., et al., Stereoselectivity of chloroperoxidase-dependent 
halogenation. Biochemistry (Easton), 1983. 22(13): p. 3271-3277. 
 
83. Melton, T.C. and S.D. Brown, The Fate of Sulfamethazine in Sodium-
Hypochlorite-Treated Drinking Water: Monitoring by LC-MS. International 
Journal of Medicinal Chemistry (Online), 2012. 68(8): p. 1-6. 
146 
 
84. Hutner, S.H., et al., Some Approaches to the Study of the Role of Metals 
in the Metabolism of Microorganisms. Proceedings of the American 
Philosophical Society, 1950. 94(2): p. 152-170. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
147 
 
 APPENDIX  
F
ig
u
re
 A
1
.1
  
M
a
s
s
 S
p
e
c
tr
u
m
s
 o
f 
A
P
A
P
 a
n
d
 i
ts
 m
e
ta
b
o
lit
e
s
 
148 
 
  C15H14N2O3   (CM2)                                                                   C14H11NO2  (CM3) 
 C15H12N2O   (CBZ)                                                                      C15H12N2O2  (CM1)          
  C14H9NO   (CM4)                                                                         C13H9N  (CM5) 
  C13H9NO   (CM6)                                                                         C15H13NO2  (CM7) 
Figure A1.2 The mass spectra of CBZ and its metabolites. 
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  C14H9NO2   (CM8)                                                                       C15H11NO3  (CM9)          
   C16H14N2O2   (CM10)                                                                  C15H12ClNO2  (CM11)          
  C14H8ClNO   (CM12)                                                                  C13H8ClN  (CM13)          
Figure A1.2 (cont.) The mass spectra of CBZ and its metabolites. 
 C13H8ClNO   (CM14)                                                                  C14H8ClNO2  (CM15)          
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C12H14N4O2S (SMZ) C12H14N4 (SM1) 
  
C12H13ClN4 (SM2) C12H12Cl2N4 (SM3) 
  
C12H11Cl3N4 (SM4) C12H13ClN4O2S (SM5) 
  
C12H12Cl2N4O2S (SM6) C12H13ClN4O3S (SM7) 
  
 Figure A1.3 The mass spectra of SMZ and its metabolites. 
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C12H11Cl3N4O2S (SM8) C12H14N4O3S (SM9) 
  
       C12H13BrN4O2S (SM5-Br)        C12H12Br2N4O2S  (SM6-Br) 
  
       C12H11Br3N4O2S  (SM8-Br)  
 
 
Figure A1.3 (cont.) The mass spectra of SMZ and its metabolites. 
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Figure A3.1 DNA sequence of full-length wide type CPO gene. 
ATGTTCTCCAAGGTCCTTCCCTTCGTGGGAGCGGTTGCCGCCCTCCCTCACTC 
CGTCCGTCAGGAGCCTGGCTCCGGCATTGGCTACCCATACGACAACAACACC 
CTGCCATATGTCGCCCCAGGTCCTACCGACTCTCGTGCTCCTTGCCCAGCTCT 
GAACGCTCTTGCCAACCACGGTTACATTCCTCACGATGGCCGTGCCATCAGC 
AGGGAGACCCTCCAGAACGCTTTCCTCAACCACATGGGTATTGCCAACTCCG 
TCATTGAGCTTGCTCTGACCAACGCCTTCGTCGTCTGCGAGTACGTTACTGGC 
TCCGACTGTGGTGACAGCCTTGTCAACCTGACTCTGCTCGCCGAGCCCCACGC 
TTTCGAGCACGACCACTCCTTCTCCCGCAAGGATTACAAGCAGGGTGTCGCC 
AACTCCAACGACTTCATCGACAAC AGGAACTTCGATGCCGAGACCTTCCAGA 
CCTCTCTGGATGTCGTTGCAGGCAAGACCCACTTCGACTATGCCGACATGAA 
CGAGATCCGCCTTCAGCGCGAGTCCCTCTCCAACGAGCTTGACTTCCCCGGTT 
GGTTCACCGAGTCCAAGCCAATCCAGAACGTCGAGTCTGGCTTCATCTTCGCC 
CTTGTCTCTGACTTCAACCTGCCCGACAACGATGAGAACCCTCTGGTTCGCAT 
TGACTGGTGGAAGTACTGGTTCACCAACGAGTCCTTCCCATACCACCTCGGCT 
GGCACCCCCCGTCTCCAGCCAGGGAGATCGAGTTCGTCACCTCCGCCTCCTCC 
GCTGTCCTGGCTGCCTCTGTCACCTCTACTCCATCTTCCCTTCCATCCGGTGCC 
ATCGGCCCAGGTGCCGAGGCTGTCCCTCTCTCCTTCGCCTCCACCATGACCCC 
ATTCCTCCTCGCCACCAATGCTCCTTACTACGCCCAGGACCCAACTCTCGGCC 
CCAACGACAAGCGTGAGGCTGCCCCAGCTGCCACCACCTCCATGGCCGTCTT 
CAAGAACCCATACCTCGAGGCCATTGGC ACCCAGGACATC AAGAACCA GCA 
GGCTTACGTCAGCTCCAAGGCTGCTGCCATGGCCTCTGCCATGGCCGCCAAC 
AAGGCCCGCAACCTTTAA 
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Figure A3.2 Amino acid sequence of full-length of wide type CPO. 
1    XEPGSGIGYP YDNNTLPYVA PGPTDSRAPC PALNALANHG YIPHDGRAIS 
51   RETLQNAFLN HMGIANSVIE LALTNAFVVC EYVTGSDCGD SLVNLTLLAE 
101  PHAFEHDHSF SRKDYKQGVA NSNDFIDNRN FDAETFQTSL DVVAGKTHFD 
151  YADMNEIRLQ RESLSNELDF PGWFTESKPI QNVESGFIFA LVSDFNLPDN 
201  DENPLVRIDW WKYWFTNESF PYHLGWHPPS PAREIEFVTS ASSAVLAASV 
251  TSTPSSLPSG AIGPGAEAVP LSFASTMTPF LLATNAPYYA QDPTLGPND 
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